The Synthetic and Biological Studies of Discorhabdins and Related Compounds

Yasufumi Wada,[†] Yu Harayama,[†]Daigo Kamimura,[†] Masako Yoshida,[†] Tomoyuki Shibata,[§]

Kousaku Fujiwara,[§] Koji Morimoto,[‡] Hiromichi Fujioka,^{*†} and Yasuyuki Kita^{*†,‡}

[†]Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka,

Suita, Osaka, 565-0871 JAPAN

[‡]College of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Nojihigashi,

Kusatsu, Shiga, 525-8577 JAPAN

[§]Shinagawa R&D Center, Daiichi Sankyo Co. Ltd., 1-2-58 Hiromachi, Shinagawa,

Tokyo, 140-0005 JAPAN

E-mail: fujioka@phs.osaka-u.ac.jp: kita@phs.osaka-u.ac.jp; Phone: *Fax:* +81-6-6879-8229;*Tel:* +81-6-6879-8225 *Fax:*+81-77-561-5829;*Tel:* +81-77-561-5829

Contents

1. Total Synthesis of prianosin B (Scheme 1)	S2
2. Synthesis of discorhabdin analogues (Scheme 2)	S2
3. ¹ H NMR and ¹³ C NMR spectra	S21
4. in vivo assay	S124
5. HCC panel assay	S126

Syntheses of *N*,*O*-acetal intermediate (**51b**) were followed by ref 37.

Total synthesis of prianosin B (1c)

NaN₃ (1.1 mg, 0.0175 mmol) was added to a solution of compound **51b** (99.7 mg, 0.175 mmol) in DMF (0.3 mL) at rt under N₂. The mixture was allowed to warm to 70 °C and stirred for 1 h. The reaction mixture was quenched by H₂O and extracted by AcOEt. Organic phase was washed by H₂O (×3) and brine (×1). Organic phase was dried over Na₂SO₄. and evaporated *in vacuo*. The residue



was purified by SiO₂ column chromatography (CH₂Cl₂/MeOH = 20/1) to give prianosin B (**1c**) (35.1 mg, 48%) as red solid; m.p. 253-255 °C; $[\alpha]^{23.0}_{D}$ +362 (c 0.405, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 2.87-2.94 (3H, m), 2.98 (1H, dd, *J* = 16.5, 4.0 Hz), 4.80 (1H, dd, *J* = 12.0, 6.5 Hz), 5.49-5.58 (1H, m), 6.30 (1H, br s), 7.54 (1H, d, *J* = 5.5 Hz), 7.78 (1H, s), 8.03 (1H, s), 8.49 (1H, d, *J* = 5.5 Hz); ¹³C NMR (125 MHz, CDCl₃) δ : 40.0, 45.6, 50.8, 56.5, 61.7, 113.7, 118.2, 119.6, 120.2, 125.3, 129.0 (2C), 143.0, 143.6, 146.1, 155.7, 167.6, 188.3; IR (KBr): 3057, 2924, 2853, 1682, 1645, 1595, 1472, 1303 cm⁻¹; HRMS (FAB) calcd for C₁₈H₁₃BrN₃O₂S [*M*+H]⁺: 413.9912, found 413.9920.

Syntheses of **15a**, **b**, **16b**, **17b**, **18b**, **38b**, **49b**, **49'b**, **50b**, **50'b** and **54b**, **54'b** were followed by ref 37.

Methyl-3-(3chloro-4-hydroxyphenyl)-2-(tritylamino)propionate (15c)

 SO_2Cl_2 (0.38 mL, 4.74 mmol) was added to a solution of **11** (1.0 g, 4.32 mmol) in AcOH (7.7 mL) and Et₂O (0.86 mL) at 0 °C under N₂. The resulting solution was warmed to rt under stirring. Then the solution was filtered through Celite pad, and washed with Et₂O. The filtrate was concentrated *in vacuo* to give **precursor 15c** (910 mg,



79%) as colorless solid; m.p. 191-192 °C; ¹H NMR (500 MHz, CD₃OD) δ : 3.06 (1H, dd, J = 14.4, 7.5 Hz), 3.16 (1H, dd, J = 14.4, 6.0 Hz), 3.81 (3H, s), 4.26 (1H, dd, J = 7.5, 6.0 Hz), 6.90 (1H, d, J = 8.4 Hz), 7.01 (1H, dd, J = 8.4, 2.1 Hz), 7.22 (1H, d, J = 2.1 Hz); ¹³C NMR (100 MHz, DMSO- d_6) δ : 34.5, 52.6, 53.2, 116.7, 119.5, 126.0, 129.0, 130.8, 152.4, 169.4; IR (KBr): 3100, 1743, 1613, 1580, 1510 cm⁻¹; HRMS (FAB) calcd for C₁₀H₁₃CINO₃ [*M*+H]⁺: 230.0584, found 230.0565 (as free base).

Et₃N (103 μ L, 0.750 mmol) was added to a solution of **precursor 15c** (100.0 mg, 0.375 mmol) in DMF (1.8 mL) at rt under N₂. After being stirred for 10 min, tritylchloride (TrCl) (104.5 mg, 0.375 mmol) was added to the resulting solution. The mixture was stirred at rt for 3 h. The reaction was quenched with H₂O and extracted with AcOEt. The organic layer was washed with H₂O and brine, dried over Na₂SO₄, and evaporated

in vacuo. The residue was purified by SiO₂ column chromatography using hexane/AcOEt (3/1) as the eluent to give **15c** (123 mg, 69%) as colorless oil: ¹H NMR (300 MHz, CDCl₃) δ : 2.60 (1H, br s), 2.85 (2H, d, *J* = 6.6 Hz), 3.05 (3H, s), 3.47-3.55 (1H, m), 5.64 (1H, s), 6.91 (1H, d, *J* = 8.2 Hz), 6.99 (1H, d, *J* = 8.2 Hz), 7.09-7.23 (10H, m), 7.40 (6H, d, *J* = 7.2 Hz); ¹³C NMR (75 MHz, CDCl₃) δ : 41.0, 51.4, 58.0, 70.9, 115.9, 126.3, 127.7, 128.7, 129.7, 130.1, 130.5, 145.7, 150.2, 174.8; IR (KBr): 3533, 3342, 1730, 1595, 1500 cm⁻¹; HRMS (FAB) calcd for C₂₉H₂₇ClNO₃ [*M*+H]⁺: 472.1679, found 472.1686.

Methyl-3-(3-iodo-4-hydroxyphenyl)-2-(tritylamino)propionate (15d)

SOCl₂ (0.52 mL, 7.16 mmol) was added dropwise to a solution of 3-iodo-*L*-tyrosine (**12**) (2.00 g, 6.51 mmol) in MeOH (13.0 mL). The suspension was heated at a reflux for 3 h. The mixture was evaporated in vacuo to give **precursor 15d** (2.30 g, 99%) as colorless solid; m.p. 201-202 °C; ¹H NMR (300 MHz, CD₃OD) δ : 3.03 (1H, dd, J = 14.4, 7.5 Hz), 3.14 (1H, dd, J = 14.4, 6.0 Hz), 3.81 (3H,



s), 4.24 (1H, dd, J = 7.5, 6.0 Hz), 6.82 (1H, d, J = 8.4 Hz), 7.07 (1H, dd, J = 8.4, 1.8 Hz), 7.22 (1H, d, J = 1.8 Hz); ¹³C NMR (75 MHz, DMSO- d_6) δ : 34.3, 52.6, 53.2, 84.8, 115.0, 126.8, 130.5, 139.5, 156.0, 169.4; IR (KBr): 3200, 1741, 1600, 1570, 1502 cm⁻¹; HRMS (FAB) calcd for C₁₀H₁₃INO₃ [*M*+H]⁺: 321.9940, found 321.9941 (as free base).

Et₃N (1.78 mL, 13.02 mmol) was added to a solution of **precursor 15d** (2.3 g, 6.51 mmol) in DMF (32 mL) at rt under N₂. After being stirred for 10 min, TrCl (1.8 g, 6.51 mmol) was added to the resulting solution. The mixture was stirred at rt for 3 h. The reaction was quenched with H₂O and extracted with AcOEt. The organic layer was washed with H₂O and brine, dried over Na₂SO₄, and evaporated in vacuo. The residue was purified by SiO₂ column chromatography using hexane/AcOEt (3/1) as the eluent to give **15d** (3.62 g, quant.) as colorless solid; m.p. 95-98 °C; $[\alpha]^{26.7}_{D}$ +15.2 (c 2.95, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ : 2.55 (1H, br s), 2.84 (2H, dd, *J* = 6.5, 2.6 Hz), 3.06 (3H, s), 3.50-3.55 (1H, m), 5.32 (1H, s), 6.92 (1H, d, *J* = 8.1 Hz), 7.07 (1H, dd, *J* = 8.1, 1.6 Hz), 7.17-7.24 (9H, m), 7.39 (6H, d, *J* = 7.2 Hz), 7.55 (1H, d, *J* = 1.6 Hz); ¹³C NMR (75 MHz, CDCl₃) δ : 40.6, 51.4, 57.9, 70.9, 85.2, 114.6, 126.4, 127.8, 128.7, 131.5, 131.6, 139.3, 145.7, 153.6, 174.7; IR (KBr): 3340, 3057, 3030, 2949, 2925, 2848, 1726, 1597, 1574, 1489, 1467, 1417 cm⁻¹; HRMS (FAB) calcd for C₂₉H₂₇INO₃ [*M*+H]⁺: 564.1036, found 564.1043.

General Procedure for the Synthesies of 17a,c,d from 15a,c,d.

Diisobutylaluminium hydride (DIBAL) (0.94 M solution in hexane, 3.23 equiv) was added dropwise to a solution of 15 (1.0 equiv) in dry CH_2Cl_2 (0.053 M solution) at -78

°C under N₂. The resulting solution was warmed to rt and stirred for 5 h. The mixture was cooled to 0 °C and quenched with H₂O. The precipitate was filtered through Celite pad and the filtrate was evaporated in vacuo. The residue was dissolved in CH_2Cl_2 and the mixture was washed with sat. *aq*. NaHCO₃ and brine, then dried over Na₂SO₄ and evaporated in vacuo. The residue was purified by SiO₂ column chromatography to give **16**.

16a (5.6 g, 95%) was obtained from **15a** (6.3 g, 14.4 mmol), DIBAL (50.5 mL, 47.5 mmol) and dry CH₂Cl₂ (280 mL). Eluent: hexane/AcOEt (2/1). **16a**: Colorless oil: ¹H NMR (CDCl₃): δ = 2.17 (dd, 1H, *J* = 13.2, 4.6 Hz), 2.42 (dd, 1H, *J* = 13.2, 9.5 Hz), 2.72-2.75 (m, 1H), 2.92 (dd, 1H, *J* = 10.8, 3.8 Hz), 3.11 (dd, 1H, *J* = 10.8, 2.2 Hz), 4.92 (br s, 1H), 6.62 (d, 2H, *J* = 8.4 Hz), 6.76 (d, 2H, *J* = 8.4 Hz), 7.17-7.31 (m, 9H), 7.53 (d, 6H, *J* = 7.3 Hz).

OH NHTr OH 16a

16c (3.9 g, 51%) was obtained from **15c** (8.15 g, 17.3 mmol), DIBAL (64.0 mL, 60.5 mmol) and dry CH₂Cl₂ (86 mL). Eluent: hexane/AcOEt (2/1). **16c**: Colorless oil: ¹H NMR (300 MHz, CDCl₃) δ : 2.14 (1H, dd, J = 13.2, 9.6 Hz), 2.41 (1H, dd, J = 13.2, 9.6 Hz), 2.64-2.80 (1H, m), 2.97 (1H, dd, J = 10.8, 3.9 Hz), 3.10 (1H, dd, J = 10.8, 2.5 Hz), 6.71 (1H, dd, J = 8.1, 1.5 Hz), 6.80 (1H, d, J = 8.1 Hz), 6.83 (1H, d, J = 1.5 Hz), 7.16-7.30 (9H, m), 7.55 (6H, d, J = 7.5 Hz); ¹³C NMR (75 MHz,



OH

NHTr

CDCl₃) δ : 37.8, 55.2, 67.9, 71.3, 115.9, 119.5, 126.5, 127.9, 128.6, 129.3, 129.7, 132.1, 146.4, 149.7; IR (KBr): 3247, 1700, 1590, 1575, 1500 cm⁻¹; HRMS (FAB) calcd for C₂₈H₂₇ClNO₂ [*M*+H]⁺: 444.1730, found 444.1721.

16d (680 mg, 90%) was obtained from **15d** (792 g, 1.40 mmol), DIBAL (4.46 mL, 4.20 mmol) and dry CH₂Cl₂ (7.0 mL). Eluent: hexane-AcOEt (2/1). **16d**: Colorless solid: ¹H NMR (300 MHz, CDCl₃) δ : 2.12 (1H, dd, J = 13.2, 4.5 Hz), 2.40 (1H, dd, J = 13.2, 9.5 Hz), 2.72-2.73 (1H, m), 2.98 (1H, dd, J = 10.9, 3.9 Hz), 3.10 (1H, dd, J = 10.9, 2.0 Hz) 6.73 (1H, d, J = 8.3 Hz) 6.78 (1H, dd, J = 8.3, 1.2 Hz)

 $\begin{array}{c} \text{(III, III), 2.72 2.75 (III, III), 2.96 (III, III, III, III), 2.96 (III, III, III, III), 5.16 (III, III, III, III, III), 2.96 (III, III, III, III), 5.16 (III, III, III, III), 2.96 (III, III, III, III), 5.16 (III, III, III), 5.16 (IIII, IIII), 5.16 (IIII, III, III), 5.16 (IIII, III), 5.16 (I$

tert-Butyldimetylsilyl chloride (TBSCl) (3.0 equiv) was added to a solution of **16** (1.0 equiv) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (5.0 equiv) in dry CH_2Cl_2 (0.13 M solution) at 0 °C under N₂. The mixture was stirred at the same temperature for 2.5 h.

The reaction was quenched with sat. aq. NaHCO₃ and extracted with CH₂Cl₂. The organic layer was washed with brine, dried over Na₂SO₄ and evaporated in vacuo. The residue was purified by SiO₂ column chromatography to give **17**.

17a (7.3 g, 84%) was obtained from **16a** (5.6 g, 13.6 mmol), TBSCl (6.2 g, 40.8 mmol), DBU (10.2 mL, 68.0 mmol) and dry CH₂Cl₂ (90 mL). Eluent: hexane/AcOEt (20/1). **17a**: Colorless solid: ¹H NMR (300 MHz, CDCl₃): δ = -0.30 (s, 3H), -0.27 (s, 3H), 0.10 (s, 6H), 0.69 (s, 9H), 0.81 (s, 9H), 2.10 (br s, 1H), 2.36 (dd, 1H, *J* = 9.0, 3.0 Hz), 2.45-2.50 (m, 1H), 2.51 (m, 1H), 2.80 (dd, 1H, *J* = 9.6, 3.0 Hz), 6.52 (d, 2H, *J* = 8.1 Hz), 6.7



(d, 2H, J = 8.1 Hz), 7.00-7.14 (m, 9H), 7.43 (d, 6H, J = 8.4 Hz); ¹³C NMR (CDCl₃): $\delta = -5.6$ (2C), -4.6, 18.0 (2C), 25.5, 25.7, 37.9, 55.3, 62.3, 70.9, 119.5, 126.0, 127.6, 128.6, 130.3, 132.2, 147.1, 153.5; IR (KBr): 2953, 2928, 1606, 1508, 1488, 1471 cm⁻¹; HRMS (FAB) calcd for C₄₀H₅₆NO₂Si₂ (*M*+H⁺) 638.3850. found 638.3834.

17c (4.9 g, 83%) was obtained from **16c** (3.9 g, 8.78 mmol), TBSCl (3.9 g, 26.3 mmol), DBU (3.9 mL, 26.3 mmol) and dry CH_2Cl_2 (44 mL). Eluent: hexane/AcOEt (20/1). **17c**: Colorless oil: ¹H NMR (300 MHz, CDCl₃) δ : -0.31 (3H, s), -0.29 (3H, s), 0.00 (6H, s), 0.67 (9H, s), 0.83 (9H, s), 1.99 (1H, br s), 2.31-2.39 (3H, m), 2.48-2.50 (1H, m), 2.73 (1H, d, *J* = 9.3 Hz), 6.52 (1H, d, *J* = 8.5 Hz), 6.57 (1H, d, *J* = 8.5 Hz), 6.81



(1H, s), 6.95-7.09 (9H, m), 7.38 (6H, d, J = 7.5 Hz); ¹³C NMR (75 MHz, CDCl₃) δ : -5.5, -5.4, -4.3, 18.1, 18.3, 25.7, 25.9, 37.8, 55.2, 62.3, 71.1, 120.2, 124.9, 126.3, 127.8, 128.6, 128.7, 131.2, 133.6, 147.2, 149.5; IR (KBr): 3327, 1596, 1494, 1471, 1462, 1448 cm⁻¹; HRMS (FAB) calcd for C₄₀H₅₅ClNO₂Si₂ [*M*+H]⁺: 672.3460, found 672.3453.

17d (883 mg, 91%) was obtained from **16d** (680 mg, 1.27 mmol), TBSCl (564 mg, 3.81 mmol), DBU (0.564 mL, 3.81 mmol) and dry CH₂Cl₂ (12.7 mL). Eluent: hexane-AcOEt (20/1). **17d**: Colorless oil: ¹H NMR (300 MHz, CDCl₃) δ : -0.35 (3H, s), -0.33 (3H, s), 0.00 (6H, s), 0.61 (9H, s), 0.80 (9H, s), 2.26-2.34 (3H, m), 2.44-2.45 (1H, m), 2.66 (1H, dd, J =



9.6, 3.3 Hz), 6.42 (1H, d, J = 8.3 Hz), 6.61 (1H, dd, J = 8.3, 2.1 Hz), 6.90-7.04 (9H, m), 7.21 (1H, d, J = 2.1 Hz), 7.33 (6H, d, J = 6.9 Hz); ¹³C NMR (75 MHz, CDCl₃) δ : -5.4, -4.0, 18.1, 18.3, 25.8, 25.9, 34.6, 37.4, 55.2, 62.3, 71.1, 90.1, 117.8, 126.3, 127.8, 128.7, 130.3, 134.2, 140.5, 147.2, 153.2; IR (KBr): 3327, 1712, 1682, 1595, 1487, 1471, 1446 cm⁻¹; HRMS (FAB) calcd for C₄₀H₅₄INNaO₂Si₂ [*M*+Na]⁺: 786.2662, found 786.2635.

General Procedure for the Syntheses of 38a,c,d from 17a,c,d.

TBAF (1.0 M solution in THF, 1.0 equiv) was added to a solution of 17 (1.0 equiv) in

dry THF (0.063 M solution) at 0 °C under N₂. The mixture was stirred at the same temperature for 0.5 h. The reaction was quenched with sat. aq. NH₄Cl and extracted with AcOEt. The organic layer was washed with brine, dried over Na₂SO₄ and evaporated in vacuo. The residue was purified by SiO₂ column chromatography to give **18**.

18a (818 mg, 95%) was obtained from **17a** (1.05 g, 1.64 mmol), TBAF (1.64 mL, 1.64 mmol) and dry THF (26 mL). Eluent: hexane/AcOEt (10/1). **18a**: Colorless oil: ¹H NMR (500 MHz, CDCl₃) δ : -0.25 (3H, s), -0.22 (3H, s), 0.74 (9H, s), 2.12 (1H, br s), 2.37 (1H, dd, *J* = 9.6, 4.6 Hz), 2.44-2.52 (3H, m), 2.83 (1H, dd, *J* = 9.6, 3.1 Hz), 6.65 (2H, d, *J* = 8.4 Hz), 6.77 (2H, d, *J* = 8.4 Hz), 7.06-7.20 (9H, m), 7.46 (6H, d, *J* = 7.5 Hz).



18c (2.75 g, 99%) was obtained from **17c** (3.35 g, 4.98 mmol), TBAF (4.98 mL, 4.98 mmol) and dry THF (79 mL). Eluent: hexane/AcOEt (10/1). **18c**: Colorless oil; ¹H NMR (300 MHz, CDCl₃) δ : -0.02 (3H, s), -0.01 (3H, s), 0.98 (9H, s), 2.23 (1H, br s), 2.60-2.68 (3H, m), 2.80-2.82 (1H, m), 3.00 (1H, dd, *J* = 9.3, 3.0 Hz), 6.91-6.97 (2H, m), 7.08 (1H, s), 7.26-7.40 (9H, m), 7.66 (6H, d, *J* = 7.5 Hz); ¹³C NMR (75 MHz, CDCl₃) δ : -5.4, 18.1, 25.9, 37.7, 55.1, 62.3, 71.1, 115.6, 119.3, 126.3,



127.8, 128.7, 129.6, 129.9, 132.9, 147.1, 149.4; IR (KBr): 3541, 3327, 3057, 3030, 2927, 2854, 1595, 1498, 1470, 1448 cm⁻¹.

18d (2.82 g, 99%) was obtained from **17d** (3.35 g, 4.39 mmol), TBAF (4.39 mL, 4.39 mmol) and dry THF (70 mL). Eluent: hexane-AcOEt (10/1). **18d:** Colorless oil: ¹H NMR (300 MHz, CDCl₃) δ : -0.02 (3H, s), -0.01 (3H, s), 0.98 (9H, s), 2.47-2.56 (3H, m), 2.80 (1H, m), 3.00 (1H, dd, J = 9.3, 3.0 Hz), 6.91-6.97 (2H, m), 7.08 (1H, s), 7.27-7.41 (9H, m), 7.66 (6H, d, J = 7.5 Hz); ¹³C NMR (75 MHz, CDCl₃) δ : -5.4, 18.1, 25.9, 37.4, 55.1, 62.2, 71.1, 85.3, 114.4, 126.3, 127.8, 128.7, 131.3, 133.8,



139.1, 147.1, 152.9; IR (KBr): 3541, 3327, 3057, 3030, 2927, 2854, 1595, 1498, 1470, 1448 cm⁻¹; HRMS (FAB) calcd for C₃₄H₄₁INO₂Si [*M*+Na]⁺: 650.1951, found 650.1964.

A solution of **18** (1.2 equiv) in 0.1 M HCl/MeOH (1.44 equiv) was stirred at rt for 0.5 h under N₂. This solution was added dropwise to a solution of **32** (1.0 equiv) in MeOH (0.345 M solution). The mixture was stirred at rt for 16 h and evaporated in vacuo. The residue was purified by SiO₂ column chromatography to give **38**.

38a (228 mg, 83%) was obtained from **18a** (446 mg, 0.851 mmol), 0.1 M HCl/MeOH (9.3 mL), **32** (260 mg, 0.709 mmol) and MeOH (1.6 mL). Eluent: CH₂Cl₂/MeOH/Et₃N (100/5/0.1). **38a**: Red solid: ¹H NMR (300 MHz, CDCl₃) δ : 0.00 (3H, s), 0.01 (3H, s), 0.92 (9H, s), 2.44 (3H, s), 2.61 (2H, d, *J* = 6.9 Hz), 2.80 (2H, t, *J* = 7.2 Hz), 3.30-3.32 (1H, m), 3.47 (2H, d, *J* = 3.0 Hz), 4.14 (2H, t, *J* = 7.2 Hz), 5.63 (1H, s), 5.95 (1H, br s), 6.74 (2H, d,



J = 8.4 Hz), 6.84 (2H, d, J = 8.4 Hz), 7.34 (2H, d, J = 8.4 Hz), 7.54 (1H, s), 8.06 (2H, d, J = 8.4 Hz); ¹³C NMR (75 MHz, CD₃OD) δ : -5.5, -5.4, 17.9, 18.2, 21.7, 25.8, 34.2, 48.3, 54.9, 61.4, 94.6, 116.0, 118.0, 122.8, 125.9, 126.3, 128.3, 128.8, 129.7, 130.1, 134.4, 145.2, 145.8, 155.7, 156.1, 169.4; IR (KBr): 3375, 1666, 1614, 1579, 1531, 1514, 1494, 1462, 1380 cm⁻¹; HRMS (FAB) calcd for C₃₂H₄₀N₃O₅SSi [*M*+H]⁺: 606.2458, found 606.2465.

38c (128.1 mg, 58%) was obtained from **18c** (231.2 mg, 0.414 mmol), 0.1 M HCl/MeOH (4.97 mL), **32** (122.9 mg, 0.345 mmol) and MeOH (1.0 mL). Eluent: CH₂Cl₂-MeOH-Et₃N (100/5/0.1). **38c**: Red solid: ¹H NMR (270 MHz, CD₃OD) δ : 0.00 (6H, s), 0.91 (9H, s), 2.42 (3H, s), 2.61 (2H, d, *J* = 6.6 Hz), 2.77 (2H, t, *J* = 8.0 Hz), 3.33-3.36 (1H, m), 3.64-3.67 (2H, m), 4.11-4.12 (2H,



m), 5.57 (1H, s), 6.75 (1H, d, J = 9.0 Hz), 6.82 (1H, d, J = 9.0 Hz), 7.03 (1H, s), 7.32 (2H, d, J = 8.9 Hz), 7.51 (1H, s), 8.03 (2H, d, J = 8.9 Hz); ¹³C NMR (75 MHz, CDCl₃) δ : -5.6, -5.5, 17.9, 18.2, 21.7, 25.8, 34.0, 48.1, 54.7, 61.3, 74.0, 86.1, 94.4, 107.4, 117.0, 117.9, 120.8, 122.7, 126.0, 126.3, 128.5, 128.8, 129.7, 130.0, 134.2, 145.9, 151.4, 156.0, 162.6, 166.8; IR (KBr): 3375, 3018, 2928, 2856, 1666, 1614, 1580, 1537, 1495, 1462, 1445, 1379 cm⁻¹; HRMS (FAB) calcd for C₄₂H₄₃ClN₃O₅SSi [*M*+H]⁺: 640.2068, found 640.2095.

38d (71.7 mg, 49%) was obtained from **18d** (171.3 mg, 0.264 mmol), 0.1 M HCl/MeOH (3.17 mL), **32** (78.4 mg, 0.200 mmol) and MeOH (0.5 mL). Eluent: CH₂Cl₂/MeOH/Et₃N (100/5/0.1). **38d**: Red solid: ¹H NMR (500 MHz, CDCl₃) δ : 0.01 (3H, s), 0.13 (3H, s), 0.85 (9H, s), 2.32 (3H, s), 2.63 (2H, d, *J* = 6.3 Hz), 2.77 (2H, t, *J* = 8.1 Hz), 3.37-3.40 (1H, m), 3.48-3.54 (2H, m), 4.03



(2H, t, J = 8.1 Hz), 5.48 (1H, s), 6.79 (1H, d, J = 7.8 Hz), 6.89 (1H, d, J = 7.8 Hz), 7.28 (1H, s), 7.30 (2H, d, J = 9.0 Hz), 7.34 (1H, s), 8.00 (2H, d, J = 9.0 Hz); ¹³C NMR (75 MHz, CDCl₃) δ : -5.5, -5.4, 18.0, 18.2, 18.8, 21.8, 23.9, 25.9, 45.4, 45.6, 53.7, 56.4, 62.0,

97.1, 107.6, 117.2, 118.0, 119.3, 126.5, 128.7, 128.9, 129.8, 130.6, 131.0, 135.4, 137.0, 139.2, 158.1, 164.5, 175.7, 186.2; IR (KBr): 3368, 2953, 2928, 2856, 1709, 1666, 1616, 1578, 1558, 1534, 1491, 1464, 1443, 1379 cm⁻¹; HRMS (FAB) calcd for $C_{42}H_{43}IN_3O_5SSi[M+H]^+$: 732.1424, found 732.1416.

General Procedure for the Syntheses of 49a, c-d, 49'c-d from 38a,c,d

PIFA (1.2 equiv) and montmorillonite K10 (1/4 mg of **38** (mg)) was added to a solution of **38** (1.0 equiv) in CF₃CH₂OH (0.03 M solution) at rt under N₂. The mixture was stirred at rt for 0.5 h and evaporated in vacuo. The residue was purified by SiO₂ column chromatography to give **49**.

49a (66.0 mg, 57%) was obtained from **38a** (115 mg, 0.190 mmol), PIFA (98 mg, 0.228 mmol), and CF₃CH₂OH(6.3 ml). Eluent: hexane/AcOEt/Et₃N (100/50/0.1). **49a**: Red solid: ¹H NMR (300 MHz, CDCl₃) δ : -0.02 (3H, s), 0.02 (3H, s), 0.84 (9H, s), 1.41 (1H, d, *J* = 13.2 Hz), 1.61 (1H, d, *J* = 13.2 Hz), 2.33 (3H, s), 2.52 (2H, t, *J* = 7.2 Hz), 3.43-3.45 (2H, m), 3.63-3.75 (3H, m), 3.99 (1H, t, *J* = 7.2 Hz), 5.99 (1H, br s), 6.12 (1H, dd, *J* = 9.9, 3.0



Hz), 6.13 (1H, dd, J = 9.9, 3.0 Hz), 6.80 (1H, dd, J = 9.9, 3.0 Hz), 6.89 (1H, dd, J = 9.9, 3.0 Hz), 7.23 (2H, d, J = 8.4 Hz), 7.35 (1H, s), 7.95 (2H, d, J = 8.4 Hz); ¹³C NMR (75 MHz, CDCl₃) δ : -5.4, -5.3, 17.5, 18.3, 21.7, 25.7, 37.5, 40.8, 49.5, 66.3, 105.5, 118.5, 121.9, 125.8, 126.4, 127.5, 128.6, 129.7, 134.6, 141.9, 145.7, 152.9, 157.3, 168.7, 186.1; IR (KBr): 3394, 1660, 1620, 1595, 1574, 1524, 1460, 1435, 1379 cm⁻¹; HRMS (FAB) calcd for C₃₂H₃₈N₃O₅SSi [*M*+H]⁺: 604.2301, found 604.2323.

49c (24.7 mg, 24%) and **49'c** (18.2 mg, 17%) were obtained from **38c** (105.6 mg, 0.165 mmol), PIFA (85.1 mg, 0.198 mmol), and CF₃CH₂OH (5.5 ml). Eluent: hexane/AcOEt/Et₃N (100/50/0.1). **49c:** Red solid: m.p. > 300 °C; $[\alpha]^{26.3}_{D}$ +225 (c 1.84, MeOH); ¹H NMR (300 MHz, CDCl₃) δ : 0.01



(3H, s), 0.02 (3H, s), 0.84 (9H, s), 1.46-1.65 (2H, m), 2.33 (3H, s), 2.52 (2H, t, J = 7.3 Hz), 3.38-3.45 (2H, m), 3.64-3.76 (2H, m), 3.97-4.04 (1H, m), 6.19 (1H, d, J = 9.9 Hz), 6.88 (1H, dd, J = 9.9, 2.7 Hz), 6.93 (1H, d, J = 2.7 Hz), 7.22 (2H, d, J = 8.4 Hz), 7.36 (1H, s), 7.72 (1H, d, J = 8.4 Hz), 7.94 (1H, d, J = 8.4 Hz); ¹³C NMR (75 MHz, CDCl₃) δ : -5.4, 17.5, 18.3, 21.7, 25.9, 36.6, 41.8, 42.9, 48.1, 49.5, 53.4, 66.1, 118.5, 121.8, 125.4, 126.1, 126.3, 128.6, 129.7, 130.2, 134.5, 145.8, 152.5, 153.2, 168.4, 179.3; IR (KBr): 3387, 3153, 2928, 1798, 1660, 1597, 1574, 1528, 1460, 1379 cm⁻¹; HRMS

(FAB) calcd for $C_{32}H_{37}CIN_3O_5SSi[M+H]^+$: 638.1912, found 638.1909.

49'c: Red solid: ¹H NMR (300 MHz, CDCl₃) δ : 0.00 (3H, s), 0.02 (3H, s), 0.84 (9H, s), 1.45-1.62 (2H, m), 2.33 (3H, s), 2.52 (2H, t, *J* = 7.5 Hz), 3.40-3.46 (2H, m), 3.64-3.73 (2H, m), 3.94-3.41 (1H, m), 5.27 (1H, br s), 6.24 (1H, d, *J* = 9.6 Hz), 6.82 (1H, d, *J* = 9.6 Hz), 7.06 (1H, s), 7.23 (2H, d, *J* = 7.8 Hz), 7.36 (1H, s), 7.93 (2H, d, *J* = 7.8 Hz); ¹³C NMR (125 MHz, CDCl₃) δ : -5.4, -5.4, 17.5, 18.3, 21.7, 25.9, 36.9, 43.0, 49.4 53.4, 66.1, 77.2, 125.4, 126.4, 128.6, 129.6, 129.7, 133.0, 134.6, 142.1, 143.5, 145.8, 148.2, 157.2, 179.2; IR (KBr): 3393, 3153, 2955, 2930, 2856, 1661, 1595, 1574, 1529, 1462, 1379 cm⁻¹; HRMS (FAB) calcd for C₃₂H₃₇ClN₃O₅SSi [*M*+H]⁺: 638.1912, found 638.1926.

49d (21.8 mg, 25%) and **49'd** (10.8 mg, 12%) were obtained from **38d** (88.4 mg, 0.121 mmol), PIFA (63.3 mg, 0.145 mmol), and CF₃CH₂OH (4.0 ml). Eluent: hexane/AcOEt/Et₃N (100/50/0.1). **49d**: Red solid: $[\alpha]^{27.4}_{D}$ -164 (c 4.50, MeOH); ¹H NMR (500 MHz, CDCl₃) δ : -0.23 (3H, s), 0.21 (3H,



s), 0.84 (9H, s), 1.36-1.68 (2H, m), 2.33 (3H, s), 2.53 (2H, t, J = 7.1 Hz), 3.38-3.49 (2H, m), 3.63-3.82 (2H, m), 3.94-4.04 (1H, m), 5.99 (1H, br s), 6.19 (1H, d, J = 9.7 Hz), 6.90 (1H, dd, J = 9.7, 2.6 Hz), 7.23 (2H, d, J = 7.4 Hz), 7.36 (1H, s), 7.49 (1H, d, J = 2.6 Hz), 7.94 (2H, d, J = 7.4 Hz); ¹³C NMR (67.8 MHz, CDCl₃) δ : -5.3, -5.2, 17.6, 18.4, 21.6, 21.8, 24.7, 25.9, 29.7, 36.7, 45.1, 49.6, 66.1, 104.0, 118.5, 121.7, 123.2, 124.1, 125.5, 126.0, 126.3, 128.5, 129.5, 129.6, 129.7, 134.4, 139.0, 143.3, 145.6, 152.7, 157.2, 160.1, 168.1, 179.5; IR (KBr): 3395, 2928, 2856, 1659, 1574, 1529, 1461 cm⁻¹; HRMS (FAB) calcd for C₃₂H₃₇IN₃O₅SSi [*M*+H]⁺: 730.1268, found 730.1266.

49'd: Red solid: ¹H NMR (270 MHz, CDCl₃) δ : 0.03 (3H, s), 0.06 (3H, s), 0.88 (9H, s), 1.60-1.65 (2H, m), 2.38 (3H, s), 2.55 (2H, t, *J* = 7.5 Hz), 3.43-3.46 (2H, m), 3.66-3.77 (2H, m), 3.97-4.04 (1H, m), 6.05 (1H, br s), 6.26 (1H, d, *J* = 9.6 Hz), 6.87 (1H, dd, *J* = 9.6, 2.5 Hz), 7.25 (2H, d, *J* = 8.4 Hz), 7.38 (1H, s), 7.69 (1H, d, *J* = 2.5 Hz), 7.96 (2H, d, *J* = 8.4 Hz); ¹³C NMR (67.8 MHz, CDCl₃) δ : -5.2 (2C), 17.7, 18.4, 21.8, 24.7, 26.0, 29.8, 36.7, 45.1, 49.4, 49.6, 66.1, 104.1, 118.5, 121.8, 123.3, 125.5, 126.0, 126.3, 128.6, 129.2, 129.6, 129.8, 134.4, 143.4, 145.7, 152.7, 157.1, 160.0, 168.1, 179.5; IR (KBr): 3391, 3153, 2928, 2856, 1794, 1655, 1575, 1528, 1462, 1382 cm⁻¹; HRMS (FAB) calcd for C₃₂H₃₇IN₃O₅SSi [*M*+H]⁺: 730.1268, found 730.1284.

General Procedure for the Syntheses of 50a, c-d, 50'c-d from 49a, c-d, 49'c-d

 $BF_3 \cdot Et_2O$ (9.4 equiv) was added to a solution of **49** (1.0 equiv) in dry CH_2Cl_2 (0.055 M solution) at 0 °C under N₂. The mixture was allowed to warm to rt for 7 h. The reaction was quenched with NaHCO₃ powder, filtered and evaporated in vacuo. The residue was purified by SiO₂ column chromatography to give **50**.

50a (35.3 mg, 87%) was obtained from **49a** (50.1 mg, 0.0829 mmol), BF₃·Et₂O (0.10 mL, 0.78 mmol), and dry CH₂Cl₂ (1.5 mL). Eluent: CH₂Cl₂/MeOH/Et₃N (100/5/0.1). **50a**: Red solid: ¹H NMR (270 MHz, (CD₃)₂CO) δ : 1.53 (1H, d, *J* = 12.0 Hz), 1.81 (1H, t, *J* = 12.0 Hz), 2.64 (3H, s), 2.83 (2H, m), 3.57-3.82 (4H, m), 4.32 (1H, m), 6.06 (2H, dd, *J* = 10.2, 2.2 Hz), 6.96 (1H, dd, *J* = 10.2, 2.2 Hz), 7.47 (2H, d, *J* = 8.4 Hz), 7.63 (1H, s), 8.06 (2H, d, *J* = 8.4 Hz); ¹³C



NMR (75 MHz, $(CD_3)_2CO$) δ : 18.0, 21.5, 38.4, 41.6, 50.4, 65.5, 111.9, 119.6, 122.5, 126.8, 127.3, 127.8, 129.4, 130.7, 135.6, 140.0, 147.0, 153.8, 158.0, 169.4, 185.6; IR (KBr): 3305, 1659, 1614, 1595, 1573, 1525, 1487, 1461, 1375 cm⁻¹; HRMS (FAB) calcd for $C_{26}H_{24}N_3O_5S [M+H]^+$: 490.1437, found 490.1429.

50c (9.0 mg, 65%) was obtained from **49c** (16.7 mg, 0.0262 mmol), BF₃·Et₂O (35 μ L, 0.276 mmol), and dry CH₂Cl₂ (1.4 mL). Eluent: CH₂Cl₂/MeOH/Et₃N (100/5/0.1). **50c**: Red solid: ¹H NMR (300 MHz, CDCl₃) δ : 1.55 (1H, d, *J* = 12.0 Hz), 1.79 (1H, d, *J* = 12.0 Hz), 2.36 (3H, s),



2.57-2.62 (2H, m), 3.54-3.56 (2H, m), 3.78-3.83 (2H, m), 4.00-4.03 (1H, m), 6.03 (1H, br s), 6.22 (1H, d, J = 9.9 Hz), 6.92 (1H, dd, J = 9.9, 2.4 Hz), 6.98 (1H, d, J = 2.4 Hz), 7.27 (2H, d, J = 8.4 Hz), 7.40 (1H, s), 7.95 (2H, d, J = 8.4 Hz); ¹³C NMR (67.8 MHz, CDCl₃) δ : 17.8, 21.7, 28.9, 29.6, 38.6, 44.2, 49.4, 59.6, 68.1, 77.2, 80.1, 118.6, 122.0, 123.3, 125.4, 126.0, 128.5, 129.8, 134.5, 145.9, 152.5, 157.4, 168.3, 191.2; IR (KBr): 3389, 2930, 1713, 1661, 1595, 1573, 1529, 1485, 1462, 1377 cm⁻¹; HRMS (FAB) calcd for C₂₆H₂₃ClN₃O₃S [*M*+H]⁺: 524.1047, found 524.1066.

50'c (5.5 mg, 65%) was obtained from **49'c** (11.9 mg, 0.0160 mmol), BF₃·Et₂O (21.4 μ L, 0.169 mmol), and dry CH₂Cl₂ (0.86 mL). Eluent: CH₂Cl₂/MeOH/Et₃N (100/5/0.1). **50'c**: Red solid: ¹H NMR (300 MHz, CDCl₃) δ : 1.56-1.57 (1H, m), 1.80-1.84 (1H, m), 2.37 (3H, s), 2.57-2.62 (2H, m), 3.54-3.59 (2H, m), 3.79-3.85 (2H, m), 3.98-4.01 (1H, m), 4.72 (1H, br s), 6.29 (1H, d, J = 9.9 Hz), 6.86 (1H, d, J = 9.9 Hz), 7.10 (1H, s), 7.27 (2H, d, J = 7.8 Hz), 7.41 (1H, s), 7.95 (1H, d, J = 7.8 Hz); ¹³C NMR (75 MHz, (CD₃)₂CO) δ : 18.0, 21.5, 37.6, 39.8, 42.4, 44.0, 47.9, 50.2, 65.2, 119.6, 125.8, 127.4, 129.4, 130.7, 131.7, 135.6, 147.0, 150.0, 158.7, 169.3, 178.9; IR (KBr): 3385, 3130, 1660, 1650, 1595, 1575, 1525, 1485, 1460, 1375 cm⁻¹; HRMS (FAB) calcd for C₂₆H₂₃ClN₃O₃S [*M*+H]⁺: 524.1047, found 524.1060.

50d (14.9 mg, 81%) was obtained from **49d** (22.1 mg, 0.030 mmol), BF₃·Et₂O (39.3 μ L, 0.303 mmol), and dry CH₂Cl₂ (1.5 mL). Eluent: CH₂Cl₂/MeOH/Et₃N (100/5/0.1). **50d**: Red solid: ¹H NMR (300 MHz, CDCl₃) δ : 1.65 (1H, d, *J* = 12.0 Hz), 1.78 (1H, d, *J* = 12.0 Hz), 2.36 (3H, s), 2.58 (2H, t, *J* = 7.2 Hz), 3.54-3.57 (2H, m),



3.79-3.85 (2H, m), 4.00-4.05 (1H, m), 6.23 (1H, d, J = 9.7 Hz), 6.94 (1H, dd, J = 9.7, 2.6 Hz), 7.27 (1H, d, J = 8.4 Hz), 7.41 (1H, s), 7.53 (1H, d, J = 2.6 Hz), 7.96 (2H, d, J = 8.4 Hz); ¹³C NMR (125 MHz, (CD₃)₂CO) δ : 18.0, 21.6, 37.1, 45.9, 50.0, 50.4, 65.4, 65.5, 119.6, 122.6, 124.3, 126.2, 127.4, 129.4, 130.2, 130.7, 135.6, 147.0, 153.8, 154.2, 166.4, 169.2, 179.7; IR (KBr): 3387, 2925, 2853, 1794, 1655, 1572, 1528, 1460, 1379 cm⁻¹; HRMS (FAB) calcd for C₂₆H₂₃ClN₃O₃S [*M*+H]⁺: 616.0403, found 616.0403.

50'd (6.3 mg, 68%) was obtained from **49'd** (10.6 mg, 0.015 mmol), BF₃·Et₂O (16.7 µL, 0.145 mmol), and dry CH₂Cl₂ (0.7 mL). Eluent: CH₂Cl₂/MeOH/Et₃N (100/5/0.1). **50'd**: Red solid: ¹H NMR (300 MHz, CDCl₃) δ : 1.93-1.98 (1H, m), 2.15-2.22 (1H, m), 2.36 (3H, s), 2.53-2.62 (2H, m), 3.51-3.55 (3H, m), 3.79-3.84 (2H, m), 6.30 (1H, d, *J* = 9.8 Hz), 6.90 (1H, d, *J* = 9.8 Hz), 7.23 (1H, s), 7.28 (2H, d, *J* = 7.5 Hz), 7.71 (1H, s), 7.95 (2H, d, *J* = 7.5 Hz); ¹³C NMR (125 MHz, (CD₃)₂CO) δ : 18.0, 21.6, 37.6, 46.2, 46.7, 50.3, 50.4, 65.3, 104.2, 119.6, 123.5, 127.4, 128.3, 129.4, 130.2, 130.7, 131.3, 147.0, 153.9, 158.9, 162.1, 169.3; IR (KBr): 3370, 2924, 1655, 1574, 1528, 1458, 1377 cm⁻¹; HRMS (FAB) calcd for C₂₆H₂₃ClN₃O₃S [*M*+H]⁺: 616.0403, found 616.0413.

General Procedure for the Synthesis of 54a, c-d, 54'c-d from 50a, c-d, 50'c-d

30% HBr-AcOH (0.75 mL/1.0 mmol of **50**) was added to a solution of **50** (1 equiv) in dry CH_2Cl_2 (0.02 M solution) at 0 °C under N₂. The mixture was stirred warming to rt for 36 h. The reaction was quenched with sat. *aq.* NaHCO₃ and extracted with CH_2Cl_2 . The organic layer was washed with brine, dried over Na₂SO₄ and evaporated in vacuo. The residue was purified by SiO₂ column chromatography to give **54**.

54a (23.5 mg, 66%) was obtained from **50a** (35.3 mg, 0.0721 mmol), 30% HBr-AcOH (67 μ L), and dry CH₂Cl₂ (3.6 mL). Eluent: hexane/AcOEt (1/1). **54a**: Red solid: m.p. > 300 °C; $[\alpha]^{26.5}_{D}$ +956 (c 0.541, MeOH); ¹H NMR (300 MHz, CDCl₃) δ : 1.69 (1H, d, *J* = 12.9 Hz), 1.92 (1H, d, *J* = 12.9 Hz), 2.34 (3H, s), 2.53-2.58 (3H, m), 2.84 (1H dd *J* = 16.8 12.9 Hz), 3.55 (1H s), 3.73-3.79 (2H m), 4.15

112), 1.92 (111, d, J = 12.9 Hz), 2.34 (311, 8), 2.35-2.38 (311, 11), 2.34 (1H, dd, J = 16.8, 12.9 Hz), 3.55 (1H, s), 3.73-3.79 (2H, m), 4.15 (1H, dd, J = 16.8, 6.0 Hz), 4.28 (1H, dd, J = 9.6, 6.0 Hz), 5.85 (1H, s), 5.89 (1H, d, J = 10.2 Hz), 7.03 (1H, d, J = 10.2 Hz), 7.25 (2H, d, J = 8.4 Hz), 7.40 (1H, s), 7.95 (2H, d, J = 8.4 Hz); ¹³C NMR (75 MHz, CDCl₃) δ : 17.8, 21.7, 27.9, 36.5, 37.5, 44.0, 44.5, 49.5, 53.4, 68.0, 75.0, 118.6, 122.1, 124.8, 125.5, 126.7, 128.6, 129.7, 134.6, 145.8, 148.3, 152.7, 157.6, 168.5, 174.9, 197.5; IR (KBr): 3392, 2941, 2842, 1660, 1595, 1569, 1523, 1488, 1458 cm⁻¹; HRMS (FAB) calcd for C₂₆H₂₄N₃O₅S [*M*+H]⁺: 490.1437, found 490.1439.

54c (3.5 mg, 71%) was obtained from **50c** (4.9 mg, 0.00935 mmol), 30% HBr-AcOH (7 μ L), and dry CH₂Cl₂ (0.47 mL). Eluent: hexane/AcOEt (1/1). **54c**: Red solid: ¹H NMR (300 MHz, CDCl₃) δ : 1.91 (1H, d, J = 12.9 Hz), 2.34 (1H, dd, J = 12.9, 2.1 Hz), 2.44 (3H, s), 2.85-2.99 (2H, m), 3.67-4.15 (7H, m), 5.48 (1H, br s), 6.36 (1H, d, J = 10.6 Hz), 7.06 (1H, d, J = 10.6 Hz), 7.45 (2H, d, J = 8.4Hz), 7.91 (1H, s), 8.09 (2H, d, J = 8.4 Hz); ¹³C NMR (75 MHz,



CDCl₃) δ : 17.8, 21.7, 28.9, 29.6, 38.6, 44.2, 49.4, 59.6, 68.1, 77.2, 80.1, 118.6, 122.0, 123.3, 125.4, 126.0, 129.8, 134.5, 145.9, 152.5, 157.4, 168.3, 191.2; IR (KBr): 3395, 2928, 2853, 1682, 1658, 1574, 1526, 1487, 1462, 1379 cm⁻¹; HRMS (FAB) calcd for C₂₆H₂₃ClN₃O₃S [*M*+H]⁺: 524.1047, found 524.1057.

54'c (2.4 mg, 57%) was obtained from **50'c** (4.2 mg, 0.00801 mmol), 30% HBr-AcOH (6 μ L), and dry CH₂Cl₂ (0.40 mL). Eluent: hexane/AcOEt (1/1). **54'c**: Red solid: ¹H NMR (300 MHz, CDCl₃) δ : 1.87 (1H, d, *J* = 13.5 Hz), 2.38 (1H, dd, *J* = 13.5, 2.1 Hz), 2.44 (3H, s), 2.78 (1H, dd, *J* = 16.8, 4.8 Hz), 2.93-2.99 (2H, m), 3.36 (1H, dd, *J* = 16.8, 13.2 Hz), 3.65-4.02 (5H, m), 4.32 (1H, dd, *J* = 13.2, 5.3 Hz),



7.22 (1H, s), 7.45 (2H, d, J = 8.7 Hz), 7.91 (1H, s), 8.09 (2H, d, J = 8.7 Hz); ¹³C NMR (75 MHz, CDCl₃) δ : 17.8, 21.7, 27.5, 29.7, 30.9, 37.7, 38.2, 44.3, 49.7, 68.2, 74.5, 118.6, 122.0, 125.9, 128.6, 129.8, 134.5, 140.8, 145.9, 152.4, 153.7, 174.9, 190.2; IR (KBr): 3400, 2928, 2853, 1682, 1659, 1595, 1574, 1526, 1489, 1462, 1377 cm⁻¹; HRMS (FAB) calcd for C₂₆H₂₃ClN₃O₃S [*M*+H]⁺: 524.1047, found 524.1071.

54d (2.8 mg, 76%) was obtained from **50d** (3.7 mg, 0.00601 mmol), 30% HBr-AcOH (9 µL), and dry CH₂Cl₂ (0.30 mL). Eluent: hexane/AcOEt (1/1). **54d:** Red solid: $[\alpha]^{21.0}{}_{D}$ +96.8 (c 0.322, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 1.78 (1H, d, *J* = 13.0 Hz), 2.00 (1H, d, *J* = 13.0 Hz), 2.43 (3H, s), 2.61-2.70 (2H, m), 2.92 (1H, dd, *J* = 16.8, 13.0 Hz), 3.61 (1H, s), 3.73 (1H, d, *J* = 12.5 Hz),



3.80-3.84 (1H, m), 3.88 (1H, d, J = 12.5 Hz), 4.23 (1H, dt, J = 17.5, 6.0 Hz), 4.36 (1H, dd, J = 13.0, 5.5 Hz), 5.89 (1H, br s), 5.97 (1H, d, J = 10.0 Hz), 7.11 (1H, d, J = 10.0 Hz), 7.33 (2H, d, J = 8.0 Hz), 7.48 (1H, s), 8.03 (2H, d, J = 8.0 Hz); ¹³C NMR (125 MHz, CDCl₃) δ ; 17.9, 21.7, 28.1, 36.6, 37.6, 44.5, 49.6, 68.1, 75.1, 109.4, 118.6, 122.2, 124.9, 125.5, 125.7, 128.7, 129.8, 134.7, 143.5, 145.8, 152.8, 157.6, 168.6, 198.5; IR (KBr): 2928, 2853, 2359, 2341, 2253, 1659, 1570, 1523, 1489, 1458; HRMS (FAB) calcd for C₂₆H₂₃ClN₃O₃S [*M*+H]⁺: 524.1047, found 524.1071.

54'd (1.4 mg, 67%) was obtained from **50'd** (2.1 mg, 0.0341 mmol), 30% HBr-AcOH (3 μ L), and dry CH₂Cl₂ (0.17 mL). Eluent: hexane/AcOEt (1/1). **54'd**: Red solid: m.p. > 300 °C; [α]^{22.0}_D -76.0 (c 0.626, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 1.79 (1H, d, *J* = 12.8 Hz), 2.04 (1H, d, *J* = 12.8 Hz), 2.41 (3H, s), 2.67 (2H, t, *J* = 7.5 Hz), 2.88 (1H, dd, *J* = 16.5, 6.0 Hz), 3.01 (1H, dd, *J* = 16.8, 13.0 Hz), 3.61 (1H, s), 3.72 (1H, d, *J* = 12.4 Hz), 3.82-3.99 (2H, m), 4.25 (1H, dt, *J*



= 18.0, 6.5 Hz), 4.31 (1H, dd, J = 12.5, 5.0 Hz), 5.85 (1H, br s), 7.32 (2H, d, J = 8.3 Hz), 7.47 (1H, s), 7.74 (1H, s), 8.01 (2H, d, J = 8.3 Hz); ¹³C NMR (125 MHz, CDCl₃) δ : 17.8, 21.7, 27.1, 29.7, 36.3, 44.4, 49.8, 63.4, 68.2, 74.8, 98.4, 102.1, 118.5, 124.4, 125.9, 128.7, 129.8, 129.8, 145.8, 152.3, 154.1, 154.3, 165.5, 168.4, 185.0, 191.4; IR (KBr): 3018, 1710, 1659, 1526, 1487, 1460; HRMS (FAB) calcd for C₂₆H₂₃ClN₃O₃S [M+H]⁺: 524.1047, found 524.1071.

Discorhabdin oxa-aromatic analogue (57)

NaN₃ (0.248 mg, 0.00382 mmol) was added to a solution of **54b** (20.8 mg, 0.0366 mmol) in DMF (0.063 mL) at rt under N₂. The mixture was allowed to warm to 70 $^{\circ}$ C and stirred for 1 h. The reaction mixture was quenched by H₂O and extracted by AcOEt. Organic phase was washed by H₂O (×3) and brine (×1), dried over



Na₂SO₄ and evaporated *in vacuo*. The residue was purified by SiO₂ column chromatography (CH₂Cl₂/MeOH = 20/1) to give **57** (8.15 mg, 54%) as red solid.; ¹H NMR (300 MHz, CDCl₃) δ : 2.10 (1H, d, J = 11.7 Hz), 2.29 (1H, d, J = 11.7 Hz), 2.79-2.82 (2H, m), 4.01-4.06 (1H, m), 4.14 (1H, d, J = 10.4 Hz), 4.57 (1H, d, J = 10.4 Hz), 5.97 (1H, s), 6.56 (1H, d, J = 9.7 Hz), 6.57 (1H, br s), 7.04 (1H, d, J = 9.7 Hz), 7.34 (1H, d, J = 5.8 Hz), 7.90 (1H, s), 8.31 (1H, d, J = 5.8 Hz); ¹³C NMR (125 MHz,

DMSO- d_6) δ : 26.0, 30.0, 35.5, 42.7, 57.7, 72.8, 80.6, 101.9, 114.9, 117.2, 117.3, 117.7, 119.3, 124.2, 132.5, 170.7, 178.1, 190.6, 191.8; IR (KBr): 2924, 1651, 1601, 1531, 1548, 1454 cm⁻¹.

Discorhabdin oxa-aromatic analogue (57')

NaN₃ (0.205 mg, 0.00315 mmol) was added to a solution of **54'b** (14.0 mg, 0.0246 mmol) in DMF (0.042 mL) at r.t. under N₂ atmosphere. The mixture was allowed to warm to 70 °C. and stirred for 1 h. The reaction mixture was quenched by H₂O and extracted by AcOEt. Organic phase was washed by H₂O (×3) and brine (×1).



Organic phase was dried over Na₂SO₄. and evaporated in vacuo. Residue was purified by SiO₂ column chromatography (CH₂Cl₂/MeOH = 20/1) to give **57'** (5.07 mg, 50%) as red solid.; m.p. >300 °C; ¹H NMR (300 MHz, CDCl₃) δ : 2.10 (1H, d, *J* = 12.8 Hz), 2.25 (1H, d, *J* = 12.8 Hz), 2.97-3.00 (1H, m), 3.15-3.23 (1H, m), 3.86-4.05 (2H, m), 4.45-4.59 (1H, m), 5.23-5.30 (1H, m), 6.32 (1H, br s), 7.26-7.49 (2H, m), 7.87-7.94 (2H, m), 8.41 (1H, d, *J* = 5.9 Hz); ¹³C NMR (125 MHz, CDCl₃) δ : 27.4, 29.1, 39.7, 40.0, 52.4, 80.8, 110.6, 112.3, 118.0, 123.6, 125.0, 129.2, 142.9, 143.3, 146.2, 158.6, 165.3, 190.5, 191.0; IR (KBr): 3057, 2930, 2856, 1682, 1645, 1599, 1535, 1504, 1485, 1461 cm⁻¹; HRMS (FAB) calcd for C₁₉H₁₅BrN₃O₃ [M+H]⁺: 412.0297, found 412.0293.

Discorhabdin oxa analogue (55)

5 M NaOMe in MeOH (9.60 μ l, 0.0480 mmol) was added to a solution of **54a** in dry THF (1.6 ml) at 0 °C under N₂. The mixture was stirred at 0 °C for 0.5 h and evaporated in vacuo. The residue was purified by SiO₂ column chromatography (CH₂Cl₂/MeOH = 5/1) to give **55** (10.3 mg, 64%) as green solid: ¹H NMR (300 MHz,



CD₃OD) δ : 2.09 (1H, d, J = 12.3 Hz), 2.44 (1H, d, J = 12.3 Hz), 2.63-2.66 (3H, m), 3.04-3.14 (1H, m), 3.60-3.66 (4H, m), 3.88 (1H, d, J = 10.8 Hz), 4.23 (1H, d, J = 8.4 Hz), 5.94 (1H, d, J = 9.6 Hz), 6.70 (1H, s), 7.08 (1H, d, J = 9.6 Hz); ¹³C NMR (75 MHz, CDCl₃) δ : 19.4, 28.9, 37.7, 38.8, 46.6, 63.7, 67.7, 76.2, 103.2, 120.3, 124.1, 124.3, 124.8, 125.9, 128.5, 155.5, 156.7, 169.4, 200.5; IR (KBr): 3350, 2931, 2852, 1651, 1602, 1556, 1537, 1523, 1488, 1434 cm⁻¹; HRMS (FAB) calcd for C₁₉H₁₈N₃O₃ [*M*+H]⁺: 336.1348, found 336.1370.

Discorhabdin oxa analogue (56)

NaH (0.902 mg, 0.0228 mmol) was added to a solution of **55** (5.10 mg, 0.0152 mmol) in dry THF (0.75 ml) at 0 °C under N₂. The mixture was stirred at 0 °C for 10 min and MsCl (1.40 μ l, 0.0182 mmol) was added to the mixture. The mixture was stirred at 0 °C for 30 min and evaporated in vacuo. The residue was purified by SiO₂



column chromatography (CH₂Cl₂/MeOH = 20/1) to give **56** (3.40 mg, 54%) as red solid; ¹H NMR (300 MHz, CDCl₃) δ : 1.78 (1H, d, *J* = 12.6 Hz), 1.99 (1H, d, *J* = 12.6 Hz), 2.61-2.66 (3H, m), 2.89 (1H, m), 3.57 (3H, s), 3.58-3.58 (2H, m), 3.71-3.89 (2H, m), 4.20 (1H,m), 4.35 (1H, dd, *J* = 12.9, 5.1 Hz), 5.89-5.92 (1H, br s), 5.94 (1H, d, *J* = 10.2 Hz), 7.08 (1H, d, *J* = 10.2 Hz), 7.26 (1H, s); ¹³C NMR (75 MHz, CDCl₃) δ : 17.7, 28.0, 31.8, 36.7, 37.6, 42.3, 44.6, 49.7, 68.1, 74.2, 109.8, 118.4, 122.1, 124.9, 125.5, 145.9, 152.8, 157.5, 159.4, 165.4, 198.5; IR (KBr): 3400, 2933, 2849, 1651, 1614, 1568, 1523, 1494, 1462 cm⁻¹; HRMS (FAB) calcd for C₂₀H₂₀N₃O₅S [*M*+H]⁺: 414.1124, found 414.1138.

59

BzCl (5.00 μ l, 0.0450 mmol) was added to a solution of **50b** (17.0 mg, 0.0300 mmol) and Et₃N (6.30 μ l, 0.0450 mmol) in dry CH₂Cl₂ (1.0 ml) at 0 °C under N₂. The resulting solution was warmed to rt for 3.0 h. The reaction was quenched with H₂O and extracted with AcOEt. The organic layer was washed with brine, dried over Na₂SO₄ and evaporated in vacuo. The residue was purified by NH



column chromatography (*n*-hexane/AcOEt = 2/1) to give **59** (11.5 mg, 57%) as red solid; ¹H NMR (400 MHz, CDCl₃) δ : 2.00-2.07 (2H, m), 2.42 (3H, s), 2.66 (2H, t, J = 8.0 Hz), 3.63-3.66 (2H, m), 4.01 (2H, t, J = 8.0 Hz), 4.15-4.17 (1H, m), 6.12 (1H, d, J = 10.4 Hz), 7.14 (1H, dd, J = 10.4, 2.8 Hz), 7.32 (2H, d, J = 8.4 Hz), 7.38 (1H, s), 7.47-7.56 (3H, m), 7.61 (1H, d, J = 7.2 Hz), 8.03 (2H, d, J = 8.4 Hz), 8.08 (2H, d, J = 8.4 Hz); ¹³C NMR (100 MHz, DMSO- d_6) δ : 15.4, 22.3, 25.9, 29.7, 52.6, 72.5, 76.2, 93.4, 98.7, 102.0, 115.5, 117.6, 123.7, 129.3, 145.4, 145.8, 147.2, 147.8, 147.9, 148.3, 155.7, 157.9, 158.3, 163.7, 165.5, 169.3, 180.0, 191.7, 198.3; IR (KBr): 2963, 2924, 1719, 1655, 1595, 1481, 1458 cm⁻¹; HRMS (FAB) calcd for C₃₃H₂₆BrN₃O₆S [*M*]⁺: 671.0726, found 671.0690.

60

PPh₃ (19.4 mg, 0.0740 mmol), DEAD (33.6 μ l, 0.0740 mmol) and DPPA (16.0 μ l, 0.0740 mmol) were added to a solution of **50b** (28.0 mg, 0.0490 mmol) in toluene (1.0 ml) at 0 °C under N₂. The resulting solution was warmed to rt for 7.0 h and evaporated in vacuo. The residue was purified by NH column chromatography (CH₂Cl₂/MeOH = 20/1) to give **60** (13.1 mg, 45%) as red solid; ¹H NMR (400 MHz,



CDCl₃) δ : 1.88 (1H, d, J = 12.8 Hz), 1.94 (1H, d, J = 12.8 Hz), 2.43 (3H, s), 2.66 (2H, t, J = 7.2 Hz), 3.67-3.85 (3H, m), 4.11-4.23 (2H, m), 5.07 (1H, d, J = 12.4 Hz), 5.94 (1H, br s), 6.01 (1H, d, J = 10.4 Hz), 7.14 (1H, d, J = 10.4 Hz), 7.33 (2H, d, J = 8.4 Hz), 7.49 (1H, s), 8.01 (2H, d, J = 8.4 Hz); ¹³C NMR (DMSO- d_6) δ : 17.3, 21.2, 43.6, 49.2, 55.1, 67.5, 80.2, 100.1, 100.7, 111.0, 121.9, 126.2, 126.8, 128.0, 130.0, 143.9, 146.0, 152.0,

155.5, 157.2, 158.9, 168.1, 189.3, 195.0; IR (KBr): 1659, 1575, 1525, 1493, 1462, 1369 cm⁻¹.

Discorhabdin P (46)

K₂CO₃ (16.3 mg, 0.118 mmol) and MeI (3.70 μ l, 0.0593 mmol) was added to a solution of discorhabdin C (**3**) (5.50 mg, 0.0118 mmol) in dry acetone (0.50 ml). The mixture was stirred at 40 °C for 12 h and evaporated in vacuo. The residue was purified by SiO₂ column chromatography (CH₂Cl₂/MeOH = 10/1) to give discorhabdin P

(3.60 mg, 64%) as red solid; m.p. > 300 °C; ¹H NMR (300 MHz, CD₃OD) δ : 1.87-1.89 (2H, m), 2.51 (2H, t, *J* = 7.5 Hz), 3.43-3.47 (2H, m), 3.73 (2H, t, *J* = 7.5 Hz), 3.82 (3H, s), 6.79 (1H, s), 7.56 (2H, s); ¹³C NMR (125 MHz, CDCl₃) δ : 18.0, 35.4, 37.6, 43.1, 45.9, 71.1, 97.1, 99.2, 106.3, 128.2, 133.1, 141.2, 149.9, 155.3, 168.0, 186.0, 193.2; UV/Vis (MeOH) λ max = 488 (log ε 0.18), 341 (1.60), 246 (3.29), 211 (3.41) nm; IR (KBr): 3387, 2926, 2503, 1649, 1566, 1523, 1493 cm⁻¹; HRMS (FAB) calcd for C₁₉H₁₈Br₂N₃O₂ [*M*+H]⁺: 477.9766, found 477.9581.

14

I₂ (8.20 g, 32.3 mmol) and 30% H₂O₂ (7.20 ml) were added to a solution of tyramine (**10**) (4.00 g, 29.2 mmol) in H₂O (140 ml). The resulting solution was warmed to 55 °C for 3.0 h. The reaction mixture was quenched by sat. *aq*. Na₂S₂O₃ and sat *aq*. NaHCO₃. The solid was filtered and washed with H₂O dried in vacuo to give **14** (10.8 g, 99%) as brown solid; m.p. 208-212 °C; ¹H NMR (300 MHz, DMSO-*d*₆) δ : 2.68 (2H, t, *J*

= 7.8 Hz), 2.98 (2H, t, J = 7.8 Hz), 3.32 (1H, br s), 7.59 (2H, s), 8.01 (2H, br s); ¹³C NMR (100 MHz, DMSO- d_6) δ : 30.9, 40.0, 87.7, 132.7, 139.3, 154.8; IR (KBr): 3349, 3127, 2997, 1589, 1471, 1454, 1300 cm⁻¹; HRMS (FAB) calcd for C₈H₁₀I₃NNaO [M+Na]⁺: 539.7794, found 539.7800.

43

Et₃N (64.3 μ l, 0.464 mmol) was added to a solution of **14** (240 mg, 0.464 mmol) in MeOH (5.5 ml) at rt for 10 min under N₂. This solution was added dropwise to a solution of **32** (138 mg, 0.387 mmol). The mixture was stirred at rt for 16 h and evaporated in vacuo. The residue was purified by SiO₂ column chromatography

 $(CH_2Cl_2/MeOH/Et_3N = 100/5/0.1)$ to give **35** (76.6 mg, 23%) as red solid; ¹H NMR (270 MHz, CD₃OD) δ : 2.42 (3H, s), 2.88 (2H, t, *J* = 7.0 Hz), 3.04 (2H, d, *J* = 7.0 Hz), 3.09 (2H, d, *J* = 7.0 Hz), 3.62 (2H, t, *J* = 7.0 Hz), 5.48 (1H, s), 7.41 (2H, d, *J* = 8.6 Hz), 7.48 (2H, s), 7.72 (1H, s), 8.05 (2H, d, *J* = 8.6 Hz); ¹³C NMR (100 MHz, CD₃OD) δ :







19.7, 21.7, 42.5, 47.2, 54.9, 94.6, 115.0, 119.4, 125.5, 128.3, 128.7, 130.0, 130.7, 131.0, 135.2, 135.8, 146.1, 148.1, 150.1, 156.6, 170.8; IR (KBr): 3262, 3053, 2101, 1681, 1614, 1566, 1556, 1531, 1525, 1494, 1469, 1446 cm⁻¹.

PIFA (55.0 mg, 0.129 mmol) was added to a solution of **35** (1.0 equiv) in CF₃CH₂OH (4.0 ml) at rt under N₂. The mixture was stirred at rt for 3.0 h and evaporated in vacuo. The residue was purified by SiO₂ column chromatography (CH₂Cl₂/MeOH/Et₃N = 100/1/0.1) to give **43** (20.6 mg, 27 %) as red solid; ¹H NMR (500 MHz, CDCl₃) δ : 1.92-1.95 (2H, m), 2.43 (3H, s), 2.64 (2H, t, *J* = 7.5 Hz), 3.48-3.54 (2H, m), 3.99 (2H, t, *J* = 7.5 Hz), 5.81 (1H, br s), 7.33 (2H, d, *J* = 8.0 Hz), 7.48 (1H, s), 7.71 (2H, s), 8.01 (2H, d, *J* = 8.0 Hz); ¹³C NMR (75 MHz, CDCl₃) δ : 21.8, 29.7, 32.8, 37.5, 48.5, 49.8, 96.4, 102.2, 111.3, 118.6, 121.7, 125.6, 126.4, 126.5, 127.2, 128.6, 129.8, 134.6, 142.1, 145.9, 162.6, 168.4, 174.1; IR (KBr): 3391, 2926, 2853, 1659, 1574, 1528, 1495, 1460, 1435 cm⁻¹; HRMS (FAB) calcd for C₂₅H₂₀I₂N₃O₄S [*M*+H]⁺: 711.9264, found 711.9258.

36a, 36b

Quinoline-5,8-dione (**20**) (25.1 mg, 0.158 mmol) was added to a solution of tyramine (**10**) (26.0 mg, 0.189 mmol) in MeOH (2.0 ml) at rt under N₂. The mixture was stirred at rt for 16 h and evaporated in vacuo. The residue was purified by SiO₂ column chromatography (CH₂Cl₂/MeOH = 20/1) to give **36a** and **36b** (less polar; (13.3 mg, 24%), polar (27.3 mg, 49%)).



36b (less polar): brown solid: ¹H NMR (300 MHz, CDCl₃) δ : 2.92 (2H, t, *J* = 7.5 Hz), 3.46 (2H, t, *J* = 7.5 Hz), 5.83 (1H, s), 6.80 (2H, d, *J* = 8.4 Hz), 7.07 (2H, d, *J* = 8.4 Hz), 7.72 (1H, dd, *J* = 7.8, 4.5 Hz), 8.44 (1H, dd, *J* = 7.8, 1.8 Hz), 8.87 (1H, dd, *J* = 4.5, 1.8 Hz); ¹³C NMR (75 MHz, CDCl₃) δ : 32.2, 43.5, 98.5, 114.9, 128.2, 128.6, 129.4, 130.0, 133.1, 146.3, 148.6, 152.3, 155.5, 179.4, 180.1; IR (KBr): 3297, 2982, 2947, 1769, 1759, 1703, 1605, 1581, 1564, 1514, 1454 cm⁻¹; HRMS (FAB) calcd for C₁₇H₁₅N₂O₃ [*M*+H]⁺: 295.1083, found 295.1079.

36a (polar): brown solid: ¹H NMR (300 MHz, CDCl₃) δ : 2.90 (2H, t, *J* = 6.9 Hz), 3.44 (2H, t, *J* = 6.9 Hz), 5.94 (1H, s), 6.11 (1H, br s), 6.80 (2H, d, *J* = 8.4, 2.1 Hz), 7.05 (2H, d, *J* = 8.4 Hz), 7.58 (1H, dd, *J* = 7.8, 4.8 Hz), 8.34 (1H, dd, *J* = 7.8, 1.8 Hz), 8.99 (1H, dd, *J* = 4.8, 1.8 Hz); ¹³C NMR (125 MHz, CDCl₃) δ : 33.5, 43.9, 101.7, 115.8, 126.4, 127.4, 128.6, 129.7, 134.3, 147.6, 149.2, 155.0, 155.7, 181.3, 181.4; IR (KBr): 3556, 2986, 2086, 1757, 1606, 1568 cm⁻¹; HRMS (FAB) calcd for C₁₇H₁₅N₂O₃ [*M*+H]⁺: 295.1083, found 295.1089.

47a, 47b

PIFA (74.3 mg, 0.173 mmol) was added to a solution of **36a**, **36b** (42.4 mg, 0.144 mmol) in CF₃CH₂OH (7.2 ml) at rt under N₂. The mixture was stirred at rt for 1.0 h and evaporated in vacuo. The residue was purified by SiO₂ column chromatography (CH₂Cl₂/MeOH = 15/1) to give **47a**, **47b** (lesspolar: 9.80 mg, 23%. polar: 20.1mg, 48 %).



47b (less polar): brown solid; m.p. 246-249 °C; ¹H NMR (300 MHz, CDCl₃) δ : 1.99 (2H, t, J = 5.7 Hz), 3.65 (2H, t, J = 5.7 Hz), 6.42 (2H, d, J = 9.9 Hz), 6.57 (1H, br s), 6.96 (2H, d, J = 9.9 Hz), 7.64 (1H, dd, J = 7.8, 4.5 Hz), 8.35 (1H, dd, J = 7.8, 1.8 Hz), 8.91 (1H, dd, J = 4.5, 1.8 Hz); ¹³C NMR (125 MHz, DMSO- d_6) δ : 32.8, 37.0, 48.6, 107.0, 126.8, 128.6, 130.6, 133.6, 146.1, 146.7, 152.4, 154.7, 176.9, 179.0, 185.1; IR (KBr): 3242, 2928, 1693, 1659, 1595, 1556, 1514, 1437, 1404 cm⁻¹; HRMS (FAB) calcd for C₁₇H₁₃N₂O₃ [M+H]⁺: 293.0926, found 293.0932.

47a (polar): brown solid: ¹H NMR (300 MHz, CDCl₃) δ : 1.98 (2H, t, J = 5.7 Hz), 3.62 (2H, t, J = 5.7 Hz), 6.39 (2H, d, J = 9.9 Hz), 7.00 (2H, d, J = 9.9 Hz), 7.59 (1H, dd, J = 7.8, 4.8 Hz), 8.35 (1H, dd, J = 7.8, 1.8 Hz), 8.93 (1H, dd, J = 4.8, 1.8 Hz); ¹³C NMR (75 MHz, CDCl₃) δ : 33.3, 37.3, 39.7, 126.3, 126.6, 127.9, 130.1, 133.9, 137.3, 148.7, 153.2, 155.0, 177.2, 180.2, 186.2; IR (KBr): 3265, 2927, 2860, 2359, 2341, 2248, 2067, 1655, 1618, 1593, 1566, 1517, 1434 cm⁻¹; HRMS (FAB) calcd for C₁₇H₁₂N₂NaO₃ [*M*+Na]⁺: 315.0746, found 315.0735.

39a, 39b

 Et_3N (0.200 ml, 1.47 mmol) was added to a solution of **11** (340 mg, 1.47 mmol) in MeOH (7.5 ml) at rt for 10 min under N₂. This solution was added dropwise to a solution of quinoline-5,8-dione (**20**) (213 mg, 1.33 mmol) in MeOH (7.5 ml). The



mixture was stirred at rt for 16 h and evaporated in vacuo. The residue was purified by SiO_2 column chromatography (CH₂Cl₂/MeOH = 10/1) to give **39a** and **39b** (less polar; (140 mg, 27%), polar (223 mg, 43%)).

39b (less polar): brown solid; ¹H NMR (300 MHz, CDCl₃) δ : 3.10 (1H, dd, J = 13.8, 6.6 Hz), 3.21 (1H, dd, J = 13.8, 5.4 Hz), 3.77 (3H, s), 4.29 (1H, dd, J = 13.8, 5.7 Hz), 5.74 (1H, s), 6.46 (1H, d, J = 7.8 Hz), 6.82 (2H, d, J = 8.4 Hz), 7.00 (2H, d, J = 8.4 Hz), 7.17 (1H, br s), 7.67 (1H, dd, J = 7.5, 4.5 Hz), 8.43 (1H, dd, J = 7.8, 1.8Hz), 8.90 (1H, dd, J = 4.5, 1.5 Hz); ¹³C NMR (75 MHz, CDCl₃) δ : 36.6, 52.9, 56.4, 101.5, 116.0, 126.0, 128.6, 130.3, 130.4, 134.6, 146.3, 147.0, 153.0, 155.9, 170.5, 179.3, 181.9; IR (KBr): 3306, 3015, 2926, 2853, 1742, 1693, 1607, 1566, 1514, 1443 cm⁻¹; HRMS (FAB) calcd

for C₁₉H₁₇N₂O₅ [*M*+H]⁺: 353.1137, found 353.1146.

39a (polar): brown solid; ¹H NMR (500 MHz, CDCl₃) δ : 3.07 (1H, dd, J = 14.0, 7.0 Hz), 3.17 (1H, d, J = 14 Hz), 3.76 (3H, s), 4.28 (1H, dd, J = 14.0, 7.0 Hz), 5.82 (1H, s), 6.35 (1H, d, J = 8.0 Hz), 6.79 (2H, d, J = 8.0 Hz), 6.95 (2H, d, J = 8.0 Hz), 7.57 (1H, dd, J =7.5, 4.5 Hz), 8.32 (1H, dd, J = 7.5, 1.5 Hz), 8.95 (1H, dd, J = 4.5, 1.5 Hz); ¹³C NMR (125 MHz, CDCl₃) δ : 37.5, 53.6, 57.0, 103.5, 116.8, 126.7, 127.3, 128.0, 130.9, 135.2, 147.1, 149.4, 155.6, 156.6, 171.4, 181.4, 182.3; IR (KBr): 3252, 2953, 1741, 1682, 1607, 1572, 1514, 1443 cm⁻¹; HRMS (FAB) calcd for C₁₉H₁₇N₂O₅ [M+H]⁺: 353.1137, found 353.1138.

40a, 40b

Et₃N (0.120 ml, 0.893 mmol) was added to a solution of tyrosinol (182 mg, 0.893 mmol) in MeOH (4.5 ml) at rt for 10 min under N₂. This solution was added dropwise to a solution of quinoline-5,8-dione (**20**) (129 mg, 0.812 mmol) in MeOH (4.5 ml). The mixture was stirred at rt for 3.0 h and evaporated in vacuo. The residue was



purified by SiO₂ column chromatography (CH₂Cl₂/MeOH = 15/1) to give **40a** and **40b** (less polar; (63.7 mg, 22%), polar (116 mg, 40%))

40b (less polar): brown solid; ¹H NMR (500 MHz, CD₃OD) δ : 2.80 (1H, dd, J = 14.0, 8.0 Hz), 2.91 (1H, dd, J = 14.0, 6.0 Hz), 3.63-3.75 (3H, m), 5.76 (1H, s), 6.67 (2H, d, J = 8.5 Hz), 7.08 (2H, d, J = 8.5 Hz), 7.77 (1H, dd, J = 8.0, 5.0 Hz), 8.39 (1H, dd, J = 7.5, 1.5 Hz), 8.81 (1H, dd, J = 5.0, 1.5 Hz); ¹³C NMR (125 MHz, CD₃OD) δ : 36.8, 57.9, 63.5, 100.4, 102.0, 116.3, 126.6, 129.8, 130.0, 131.4, 135.5, 150.6, 153.5, 175.2, 179.6, 183.1; IR (KBr): 3287, 2922, 2853, 1730, 1693, 1605, 1566, 1556, 1514, 1462 cm⁻¹; HRMS (FAB) calcd for C₁₈H₁₇N₂O₄ [M+H]⁺: 325.1188, found 325.1173.

40a (polar): brown solid; ¹H NMR (400 MHz, CD₃OD) δ : 2.70 (1H, dd, J = 13.6, 6.0 Hz), 2.81 (1H, dd, J = 13.6, 6.0 Hz), 3.53-3.65 (3H, m), 5.74 (1H, s), 6.57 (2H, d, J = 8.0 Hz), 6.97 (2H, d, J = 8.0 Hz), 7.56 (1H, dd, J = 7.2, 4.4 Hz), 8.28 (1H, d, J = 7.2 Hz), 8.76 (1H, d, J = 3.6 Hz); ¹³C NMR (100 MHz, CD₃OD) δ : 36.8, 57.8, 63.4, 101.4, 116.2, 116.3, 128.0, 129.7, 131.4, 135.8, 150.1, 150.3, 155.3, 157.2, 182.0, 182.6; IR (KBr): 3336, 2924, 2853, 1732, 1685, 1600, 1568, 1514, 1462 cm⁻¹; HRMS (FAB) calcd for C₁₈H₁₆N₂NaO₄ [*M*+Na]⁺: 347.1008, found 347.1008.

48b

1-(toluene-4-sulfonyl)-1H-indole-4,7-dion e (**23**) (228 mg, 0.755 mmol) was added to a solution of tyramine (**10**) (114 mg, 0.831 mmol) in MeOH (8.3 ml) at rt under N₂. The mixture was stirred at rt for 18 h and evaporated in vacuo. The residue was purified by SiO₂ column chromatography



(*n*-hexane/AcOEt = 3/1) to give **37a** (polar: 116 mg, 32%), **37b** (less polar: 60.7 mg, 17%).

PIFA (65.8 mg, 0.153 mmol) was added to a solution of **37b** (60.7 mg, 0.139 mmol) in CF₃CH₂OH (7.0 ml) at rt under N₂. The mixture was stirred at rt for 1.0 h and evaporated in vacuo. The residue was purified by SiO₂ column chromatography (*n*-hexane/AcOEt = 3/1) to give **48b** (28.3 mg, 47%) as brown solid.

¹H NMR (400 MHz, CDCl₃) δ : 1.82 (2H, t, *J* = 6.0 Hz), 2.42 (3H, s), 3.46-3.50 (2H, m), 6.07 (1H, br s), 6.28 (2H, dd, *J* = 8.4, 1.6 Hz), 6.62 (1H, d, *J* = 4.0 Hz), 6.76 (2H, d, *J* = 8.4, 1.6 Hz), 7.27 (2H, d, *J* = 8.4 Hz), 7.63 (1H, d, *J* = 3.2 Hz), 7.95 (2H, dd, *J* = 8.4, 1.6 Hz); ¹³C NMR (125 MHz, CDCl₃) δ : 21.8, 34.0, 37.6, 39.4, 105.8, 106.7, 126.0, 127.8, 127.9, 129.3, 129.6, 132.7, 133.8, 143.8, 145.9, 153.2, 171.4, 177.8, 185.9; IR (KBr): 3372, 2359, 2341, 1658, 1620, 1589, 1541, 1510, 1462 cm⁻¹; HRMS (FAB) calcd for C₂₃H₁₉N₂O₅S [*M*+H]⁺ 435.1015, found 435.1021.

¹H NMR and ¹³C NMR spectra







DFILE 041763Cnmr-1.als COMNT single pulse decoupled gated DATIM 19-12-2009 22:05:10 OBBNUC 13C EXMOD single_pulse_dec OBFRQ 100.53 MHz OBFIN 5.86 Hz FREQU 55.86 Hz FREQU 25125.24 Hz FREQU 25135 C FREQU 25125.24 Hz FREQU 26000 sec FREC 1H 19.2 c FWI 19.2 c FWI 19.2 c FWI 19.2 c FXRFF 0.12 Hz NH2· HCI <u>-</u> CO₂Me precursor 15c \overline{O} НО PPM 0 25 849.23 53.154 50 _ ____ 75 100 6₽८.9II -₽IZ.0II -125 _____ 132.960 _____ 130.049 _____ 130.765 150 754.221 — 078.0ði — 175





S 26













S 30



no 32



DFILE Dron prellc.als

COMNT Dron prellc.als

DATIM Sat Dec 19 23:51:54 2009

OBNUC 13C

OBNUC 13C

EXMOD BCM

OBFRQ

OBFRU

132

CONUT 13C

CONUC 13C

CBFRQ

DBFRQ

0BFRQ

75.45 MHz

0BFR1

1840.00 Hz

0BFR1

1840.00 Hz

0BFR1

1840.00 Hz

0BFR2

20356.23 Hz

SCANS

424

ACQTM

1.6097 sec

PU

1.3200 sec

PU

1.4.50 usec

PU

IRNUC 1H

20.9 c

SLVNT CDCL3

SLV

SL












E:\tyrosinol TBSx2 no haloge Fri Nov 18 19:44:25 2005 13C BCM 75.45 MHz 124.00 KHz 1840.00 Hz 32768 20356.23 Hz 20356.23 Hz 1.6097 sec 1.3900 sec 4.50 usec nz Hz OTBS υ 22.5 0.00 1.20 25 ,NHT OTBS 17a CDCL3 1HDF1LE DATIM DATIM DATIM DATIM DATIM DATIM OBFTM OBFTV OBFTV OBFTV OBFTV OBFTV OBFTV OBFTV DBFTV SCANS SCANSC ₽629°S-2863°S-200°₽-PPM -0 17.9704 25.5088 25.5088 25.5088 25.7225 25.7255 ŝ A DAY MALE 37.9220 **₹8.9624** 50 *LL*92.28 , 62.2553 71.2498 76.4031 76.4031 77.2498 100 للرام ومقاعد فتكفك فلتع 113°4030 152°3382 152°3382 153°2044 130°52044 135°1880 125 E: \tyrosinol TBSx2 no halogen C13-2.als 0101.741 150 353.4638 فيترالبك فاستانا أكالاخرب كملحان للبأر فإستانه واستأزيت وورا أكريتاني يلساني حاقل ولي 175 الفزارية والمستكمان والمستحد المستحد مستحد مستحد مستحد مستحد مستحد مستحد مستحم مستحد مستحد مستحد مستحم مستحد مستحم مستحد مستحد مستحد مستحم مستح 200

















 DFILE Dron pre37d.als

 COMNT Dron pre37d

 DATIM Sun Dec 20 00:30:57 2009

 OBNUC 13C

 OBSEQ
 75.45 MHz

 OBSET
 124.00 KHz

 OBSEN
 124.00 KHz

 OSSANS
 12697 sec

 PD
 1.3900 sec

 PD
 1.3900 sec

 PD
 1.500 sec

 PD
 1.00 PPm

 CTEMP
 20.2 c

 SLVNT CDCL3
 77.00 PPm

 ER
 77.00 PPm

 SLANIN
 24





























C:\Documents and Settings\user\ff mono-I spiro-shita 1H 2 Mon Jan 23 23:36:36 2006 1H NON 270.05 MHz 112.00 KHz 5800.00 Hz 33268 5800.00 Hz 33268 5800.00 Hz 33268 5800.00 Hz 33268 5800.00 Hz 33268 5402.40 Hz 33268 6.0655 sec 0.9350 sec 0.9350 sec 0.9350 sec 0.0350 sec 0.000 ppm 0.12 Hz 0.012 Hz	O S S S S S S S S S S S S S S S S S S S
DFILE COMNT DATIM DATIM DATIM DATIM DENUC EXMOR FREQU SCANS ACQTM PD PD PD PD PD PD FRUC CTEMP PD RMT RAIN RGAIN	Ë
09E0.0 T950.0	BOT9
TS78.0	
968 [†] · T 5025 · T 6T09 · T 9 [†] [†] 9 · T	
	- 1.98
3.4308 3.4638 3.6987 3.6987 3.7320 3.7320 3.7320 3.7320 3.7320	21.1 10.2 11.2 11.2
\$LE0.\$-/	
TSF0.9 5672.9 T082.9 TSF8.9 T958.9 T958.9	»
H 6681.7	60 · T
T 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	00.2 - 00 - 00
06790.7	













5 65





















Difference NOE Experiment







DFILE 041569down.als COMNT 041569down.als DBUTC TH APr 30 00:19:04 2009 OBNUC 1H 200 00:19:04 2009 EXMOD NON 300.40 MHz OBFER 130.00 KHz OBFER 130.00 KHz OBFER 130.00 La SCANS 5.4559 sec FREQU 6006.01 Hz SCANS 5.4559 sec FREQU 6006.01 Hz FREQU 6006.01 Hz SCANS 5.4559 sec PD 1.5440 sec PD 2.50 PD 1.6 FRUC 1H 2.1.6 C FRUC 2H 2.1











DFILE 041569uppureCnmr-1.als COMNT single pulse decoupled gated DBNUC 13C EXMOD single_pulse_dec DBFRQ single_pulse_dec DBFRQ 100.53 MHz OBFRY 5.35 KHz OBFRY 25.34 Hz 5.35 KHz OBFRY 26214 Hz 5.35 KHz 0BFRY 26214 Hz 5.31 Hz 00107 25125.24 Hz 5.35 KHz 0.000 sec PU 25125.24 Hz 5.31 Hz 1.0433 sec PU 25125.24 Hz 5.31 Hz 2.0000 sec PU 3.17 usec PU 3.17 usec PU 3.17 usec PU 21.5 C PU 21.5 C





DFILE no-halogen disco O-cycle no-' COMMT Wed Dec 28 12:02:30 2005 DBNUC 1H EXMOD NON DBERG 300.40 MHz EXMOD NON 300.40 HHz OBERG 130.00 HHz OBERT 130.00 HHz OBERT 130.00 HHz ACPU 606.01 Hz SCANS 5.4556 sec PM1 1.0000 sec PM1 5.60 usec TRNUC 1H 2.4559 sec PM1 2.4556 sec PM1 2 ZI 55 0 ZI PPM
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1</t 1.20 00'T 3.22 8T'T * 96.5 1.24 80't \$26.8 1.02 6 968.9 7.061 7.092 1.01 1.04 >4 - ∞ DFILE no-halogen disco O-cycle no-' COMNT Thu Dec 29 08:52:02 2005 OBERQ T5.45 MHZ OBERQ T5.45 MHZ OBERT 1840.00 HZ OBERT 1840.00 HZ OBERT 1840.00 HZ POINT 32768 FREQU 20356.23 HZ SCAN 1.6097 sec PD 1.3900 sec PD 1.3900 sec PD 1.3900 sec PD 20.7 c SLVNT CD30D 1.2 HZ REALN 2.12 HZ



ΖI

ΣI

Ś

0

55

DFILE N-Ms debrormo disco O-cyclic CONNT Msun Jan 29 11:58:59 2006 OBNUCL HM Sun Jan 29 11:58:59 2006 OBRUN NON EXMOD NON OBFRQ 300.40 MHz OBFIN 1150.00 KHZ OBSET 130.00 KHZ OBSET 130.00 KHZ OBSET 1150.00 HZ POLNT 32768 HZ SCANS 6006.01 HZ SCANS 5.4559 SEC PD 1.5440 SEC PD 1.5420 SEC PD 1.5420 SEC PD 1.5460 SEC PD 1.5440 SEC PD 1.5440 SEC PD 1.540 SEC PD 1.540 SEC PD 1.5440 SEC PD 1.540 SEC PD 1





DFILE N-Ms debrormo disco O-cyclic COMNT Sun Jan 29 14:53:59 2006 DBNCC 13C EXMOD BCM 75.45 MHz OBERQ 75.45 MHz OBERT 124.00 Hz POINT 32769 Hz POINT 32769 Hz POINT 20356.23 Hz SCANS 1.600 Hz POINT 1.600 Hz POINT 1.600 Hz POINT 2.0356.23 Hz SCANS 1.600 Hz POINT 1.600 Sec PD 1.3900 Sec PD 1.3900 Sec PW1 1.600 Sec PW1 2.0356.23 Hz SCANS 2.3450 Sec PW1 2.000 Sec PW1 2















-2

Brills no 733 disco F.als COMNT DATIN Sun Aug 21 10:54:45 2005 OBERQ NON EXMOD NON EXMOD NON EXMOD NON EXMOD NON DBERQ OBERQ OBERQ OBERQ SCAND







DFILE 041296.als DATM Tu 541296 DATM Tue Jul 22 20:53:57 2008 OBNUC 1H EXMOD NON 300.40 MHz OBFRQ 3300.40 MHz OBFIN 1130.00 KHz OBFIN 132768 FREQU 6006.01 Hz SCANS 6006.01 Hz SCANS 5.4559 sec 1.5440 sec PD 2.49 ppm EXNUC 1H 19.9 c SLVNT DMSO 2.49 ppm EXCTM 21 Hz SLVNT DMSO 2.49 ppm EXCTM 21 Hz SLVNT DMSO 2.49 ppm EXCTM 21 Hz SLVNT DMSO 2.49 ppm











 DFILE 041300 up.als

 COMNT 041300 up

 DATUT Thu Aug 21 20:06:08 2008

 OBFRQ 000 non

 SXMOD non

 DBFRQ 000 MHz

 OBFRQ 000 MHz

 OBFRQ 000 MHz

 OBFRQ 100 000 Hz

 PREQU 10000 Hz

 FREQU 10000 Hz

 SCANS 1.6394 sec

 PW1

 FRUC 1H

 5.40 usec

 PW1

 FRUC 1H

 SCANS 1.6394 sec

 PW1

 SCANS 1.6394 sec

 PW1

 SCANS 1.6394 sec

 PW1

 SCANS 2.00 sec

 PW1

 SCANS 2.1.0 c

 FW1

 SCANS 2.1.0 c

 FW1

 SCANS 2.1.0 c

 FW1

 SCANS 2.1.0 c

 SCANS 2.1.0 c





DFILE 041300 Churr als COMNT 041300 Churr DATIM Fri Aug 22 08:46:08 2008 OBNUC 13C EXMOD BCM 75.45 MHz OBFRQ 75.45 MHz OBFRN 124.00 KHz OBFIN 124.00 KHz OBFIN 1840.00 Hz POINT 32768 POINT 32768 FREQU 20356.23 Hz SCANS 10605 SC ACQTM 1.3900 SC PD 1.3300 SC PD 1.33000 SC PD 1.3300 SC PD 1.3300 SC PD 1.3300













....







_ •

Supplementary Material (ESI) for Organic & Biomolecular Chemistry This journal is (c) The Royal Society of Chemistry 2011





٦




.





٦

S 112





S 114





ъ



in vivo assay

Drug efficacy test

1) oxa analogue (**54a**)



Tumor volume (mm₃) (average/SE)

	,					
Grouping	7	10	14	17	21	24
1. control	183	342	595	844	1141	1341
	±14	±49	±37	±57	±96	±134
2. 54a 40 mg/kg	193	354	631	901	1213	1518
	±10	±27	±52	±60	±83	±103
3. 54a 20 mg/kg	179	310	497	774	1071	1381
	±13	±37	±37	±59	±85	±116
4. 54a 10 mg/kg	185	315	517	770	1013	1288
	±12	±38	±58	±92	±108	±127

Tumor volume (mm₃) (% inhibition)

· ·	5) (/					
	Grouping	7	10	14	17	21	24
	2. 54a 40 mg/kg	-5	-4	-6	-7	-6	-13
	3. 54a 20 mg/kg	2	9	16	8	6	-3
	4. 54a 10 mg/kg	-1	8	13	9	11	4

Body weight (g) (average/SE)

	•	/						
Grouping	7	9	10	11	14	17	21	24
1. control	20.8	20.7	21.3	20.6	21.2	20.9	20.6	20.7
	±0.5	±0.4	±0.5	±0.5	±0.6	±0.7	±0.8	±0.8
2. 54a 40 mg/kg	21	20.5	21.2	20.4	21.2	20.9	21	21.3
	±0.5	±0.3	±0.4	±0.4	±0.5	±0.6	±0.6	±0.7
3. 54a 20 mg/kg	21.8	21.7	22.2	21.5	22	21.8	22.1	22.1
	±0.3	±0.2	±0.2	±0.2	±0.3	±0.3	±0.6	±0.5
4. 54a 10 mg/kg	19.9	20	20.2	19.6	20.1	20.4	20.5	20.5
	±0.6	±0.7	±0.7	±0.7	±0.7	±0.6	±0.7	±0.8

2) discorhabdin P (46)



Tumor vo	lume	(mm_3)	(average)	
I willor i c	101110	(11115)	(4, 61466)	

Grouping	7	10	14	17	21	25
control	169	341	703	970	1275	1557
46 20 mg/kg	175	225	487	880	924	1772
46 10 mg/kg	167	195	362	603	1054	1521
46 5 mg/kg (3times/w×2w)	167	301	643	823	1348	1647
46 2 mg/kg (3times/w×2w)	166	310	567	809	1259	1792
46 1 mg/kg (3times/w×2w)	172	294	590	871	1283	1786

Tumor volume (mm₃) (% inhibition)

Grouping		10	14	17	21	25
46 5 mg/kg (3times/wx2w)	1	12	9	15	-6	-6
46 2 mg/kg (3times/wx2w)	2	9	19	17	1	-15
46 1 mg/kg (3times/wx2w)	-2	14	16	10	-1	-15

Body weight change (g) (average/SE)

Grouping	7	8	9	10	11	14	15
control	0	0.2	-0.3	-0.2	-0.4	-0.2	-0.4
46 20 mg/kg	0	-1.1	-3	-2.8	-1.7	-0.9	-1.2
46 10 mg/kg	0	-2	-4	-5.1	-5.8	-4.5	-4.2
46 5 mg/kg (3times/w×2w)	0	-0.3	-1.2	-1.5	-1.5	-0.9	-1.3
46 2 mg/kg (3times/w×2w)	0	-0.2	-0.6	-0.4	-0.1	-0.6	-1
46 1 mg/kg (3times/w×2w)	0	0.2	0	-0.3	-0.2	-0.5	-1
Grouping	16	17	18	21	22	23	25
control	0	0.3	-0.2	-1.8	-1.9	-1.5	-0.8
46 20 mg/kg	-1	-0.4	-0.3	0	0.4	0.2	0.3
46 10 mg/kg	-3	-2.4	-2.1	-1.1	-1.1	-1.2	0.3
46 5 mg/kg (3times/w×2w)	-1	-0.3	-0.5	-0.3	-0.5	-0.7	-0.7
46 5 mg/kg (3times/w×2w) 46 2 mg/kg (3times/w×2w)	-1 -1	-0.3 -1.1	-0.5 -1.4	-0.3 -1.4	-0.5 -1.5	-0.7 -1.4	-0.7 -1.1

HCC panel assay

[83 drugs] 4-Hydroperoxycyclophosphamide 6-Mercaptopurine 6-Thioguanine Aclarubicin Actinomycin-D Amsacrine aragusterol A Bleomycin hydrochloride Busulfan Camptothecin Carboplatin Carboquone Carmofur Cisplatin Clofarabine CNDAC Colchicine Cytarabine Dacarbazine Daunorubicin hydrochloride DMDC dihydrate Docetaxel Dolastatin 10 Doxifluridine Doxorubicin hydrochloride E7010 Edatrexate Ellipticine Enocitabine Epirubicin Estramustine phosphate sodium Etoposide FK317 FK973 Fluorouracil FUdR FUR Gemcitabine monoHCl Genistein **ICRF-154** ICRF-193 Indisulam Interferon-a Interferon-β Interferon-y Irinotecan hydrochloride **KRN5500** KW2170 KW2331 L-Asparaginase Melphalan

Methotrexate Mitomycin-C Mitoxantrone dihydrochloride Navelbine NC-190 Nedaplatin Neocarzinostatin Nimustine hydrochloride Nitrogen mustard N-oxide hydrochloride NK109 hydrogensulfate NK611 hydrochloride Oxaliplatin (1-OHP) paclitaxel Peplomycin Pirarubicin **PSC833** Ranimustine SM-5887 SM-5887-13-OH **SN-38** Soblidotin SU5416 **TAC-101** Tamoxifen citrate **TAS-103** Tegafur Thiotepa **TNP-470** Toremifene citrate Vinblastine sulfate Vincristine sulfate Vindesine sulfate

The result of HCC panel assay

		oxa	oxa analogue (54b)		discorhabdin A (1a)			
		log GI ₅₀	log TGI	log LC ₅₀	log GI ₅₀	log TGI	log LC ₅₀	
	HBC-4	-6.67	-6.30	-5.84	-5.66	-5.26	-4.72	
	BSY-1	-6.73	-6.31	-5.79	-5.82	-5.45	-5.08	
Br	HBC-5	-7.25	-6.72	-6.32	-5.79	-5.49	-5.19	
	MCF-7	-6.69	-6.35	-6.01	-5.67	-5.31	-4.00	
	MDA-MB-23	-6.53	-6.10	-5.17	-5.56	-5.08	-4.14	
	U251	-5.72	-5.46	-5.19	-5.45	-4.87	-4.22	
	SF-268	-6.38	-5.85	-5.30	-5.53	-5.01	-4.23	
CNS	SF-295	-5.66	-5.42	-5.19	-4.98	-4.57	-4.16	
CIND	SF-539	-6.36	-5.93	-5.36	-5.61	-5.29	-4.88	
	SNB-75	-5.57	-5.33	-5.09	-4.79	-4.45	-4.10	
	SNB-78	-6.20	-5.73	-5.30	-5.57	-5.01	-4.36	
	HCC2998	-6.60	-6.13	-5.24	-5.62	-5.20	-4.54	
	KM-12	-5.69	-5.25	-4.50	-4.84	-4.49	-4.13	
Co	HT-29	-7.41	-5.95	-5.31	-5.49	-4.96	-4.39	
	HCT-15	-6.64	-6.37	-6.10	-5.47	-4.91	-4.20	
	HCT-116	-6.94	-6.42	-5.36	-5.62	-5.20	-4.36	
	NCI-H23	-6.39	-5.75	-5.14	-5.25	-4.59	-4.00	
	NCI-H226	-5.67	-5.38	-5.10	-4.58	-4.18	-4.00	
	NCI-H522	-6.76	-6.45	-6.13	-5.73	-5.37	-5.01	
Lu	NCI-H460	-5.96	-5.53	-5.10	-5.14	-4.61	-4.14	
	A549	-5.69	-5.29	-4.74	-4.89	-4.49	-4.08	
	DMS273	-6.60	-6.18	-5.55	-5.63	-5.20	-4.42	
	DMS114	-6.79	-6.45	-6.11	-5.73	-5.42	-5.11	
Me	LOX-IMVI	-6.55	-6.14	-5.10	-5.72	-5.29	-4.00	
	OVCAR-3	-7.51	-6.90	-5.51	-5.49	-5.04	-4.13	
	OVCAR-4	-6.75	-6.47	-6.19	-5.50	-5.02	-4.47	
Ov	OVCAR-5	-6.70	-6.43	-6.16	-5.61	-5.24	-4.73	
	OVCAR-8	-6.46	-5.54	-4.00	-5.47	-4.45	-4.00	
	SK-OV-3	-5.58	-5.13	-4.56	-4.82	-4.51	-4.20	
Re	RXF-631L	-5.74	-5.41	-5.08	-4.96	-4.60	-4.25	
	ACHN	-6.40	-5.80	-4.97	-5.50	-5.02	-4.00	
	St-4	-5.50	-5.13	-4.30	-4.89	-4.37	-4.00	
	MKN1	-6.52	-5.87	-5.19	-5.51	-4.98	-4.24	
St	MKN7	-6.69	-6.25	-5.51	-5.51	-5.16	-4.20	
50	MKN28	-6.62	-6.16	-5.19	-5.53	-5.01	-4.00	
	MKN45	-6.61	-6.28	-5.81	-5.51	-4.93	-4.35	
	MKN74	-6.76	-6.32	-5.42	-5.58	-5.21	-4.19	
vPa	DU-145	-5.87	-5.56	-5.24	-4.86	-4.51	-4.16	
лгg	PC-3	-6.25	-5.50	-4.69	-5.37	-4.71	-4.00	

COMPARE program of compounds 54b and 1a

	Br O U U U U U U U U U U U U U U U U U U		$S \xrightarrow{H} H = 0$
	discort	nabdin o	xa analogue (54b)
Rank	compounds	r	Molecular Targets/Drug Type
1	Vincristine	0.433	tubulin
			anti-neoplastic antibiotic. inhibits
2	Actinomycin-D	0.430	RNA polymerase and is a potent
			inducer of apoptosis
3	Vinblastine	0.392	tubulin

	discorhabdin A (1a)								
Rank	compounds	r	Molecular Targets/Drug Type						
1	Nitrogen	0 421	DNA alkylating agent						
1	mustard	0.421	DINA aikylating agent						
2	Vincristine	0.413	tubulin						
3	Vinblastine	0.390	tubulin						

Peason correlation coefficient were calculated using the following formula:

$$r = \frac{\sum_{i=1}^{n} (x_i - \overline{x})(y_i - \overline{y})}{\sqrt{\sum_{i=1}^{n} (x_i - \overline{x})^2} \sqrt{\sum_{i=1}^{n} (y_i - \overline{y})^2}}$$

Where x_i and y_i are log GI₅₀ of drug A and drug B, respectively, against each cell line, and \overline{x} and \overline{y} are the mean values of x_i and y_i respectively.